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Abstract 
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Abstract 
An adaptive immune response is initiated upon recognition of antigen presented on the 
surface of antigen-presenting cell (APC) by T cells. CD8 T cells primed in the liver by 
antigen-presenting liver sinusoidal endothelial cells (LSECs) develop into nonresponsive 
cells with a memory-phenotype. Liver-primed CD8 T cells are not terminally committed 
to this unique differentiation state but develop into effector cells upon infection. The 
adaptive immune response is balanced by co-stimulatory and co-inhibitory signals. 
LSEC-primed CD8 T cells require co-inhibitory PD-L1 signals delivered by LSECs to 
develop into a nonresponsive/memory state. In this study we investigated the relation 
between PD-L1/PD-1 signaling at early time-points and formation of an immune 
synapse, which may play a role in further development of effector function in T cells.  
Upon antigen-specific interaction of APC and T cell, an immunological synapse is formed 
at their interface that is required for signaling exchanged between these cells. In this 
study, we demonstrate that LSEC-CD8 T cell interaction results in multifocal immune 
synapse formation. Furthermore, although the development of nonresponsive state of 
liver-primed CD8 T cells requires co-inhibitory PD-L1/PD-1 signaling, the formation and 
phenotype of the immune synapse did not. Not only the absence of PD-L1 signaling, but 
also delivery of CD28 co-stimulatory signals can prevent differentiation of CD8 T cells 
into nonresponsiveness after priming by LSEC. Interestingly, we found that co-
stimulation via CD28 was able to overcome this unique differentiation program when 
introduced between 0 and 36 hours of LSEC-CD8 T cell coculture, indicating that co-
inhibitory PD-1 signaling is required to be integrated during this time to induce typical 
liver-primed non-responsive memory like T cells.  
Gene expression analysis identified the small GTPase ADP-ribosylation factor 4D (Arl4d) 
to be overexpressed in LSEC-primed CD8 T cells, compared to DC-primed CD8 T cells. 
More interestingly, Arl4d expression in CD8 T cells during LSEC-priming is dependent 
on PD-L1/PD-1 signaling. Similar to T cells activated in the presence of co-inhibitory PD-
1 signaling, in the presence of Arl4d expression IL-2 production by CD8 T cells is 
attenuated in vitro and in vivo. In addition, Arl4d restricts effector CD8 T cell 
development and expansion on viral infection. Taken together, this study reveals a new 
as-yet undiscovered inhibitory function of Arl4d in modulating T cell immunity most 
likely via the regulation of IL-2 availability. Therefore, Arl4d might act downstream of 
co-inhibitory PD-1 signaling and thus play role in the regulation of CD8 T cell immunity. 
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1 Introduction 
 
1.1 The immune system 
The human body is under constant assault from pathogens. There exist two types of 
immunity that protect the host from infection: innate and adaptive immunity. Most of 
the microorganisms, encountered daily in the life of healthy individuals, are detected 
and destroyed within minutes or hours by the mechanisms of innate immunity, which 
serve as the first line of defense (Mueller et al., 2013; Iwasaki and Medzhitov, 2010; 
Murphy, 2012). Innate immunity relies on a limited number of germ-line encoded 
receptors, called pattern recognition receptors (PRRs) that recognize molecules typical 
of a microorganism, called pathogen-associated molecular patterns (PAMPs). The innate 
immune cells bearing these receptors, like macrophages, dendritic cells (DCs), mast 
cells, neutrophils and natural killer cells (NK) mature upon an inflammatory response 
and are capable of eradicating pathogens. However, in some cases, the innate immune 
system is unable to deal with an infection, requiring the involvement of the adaptive 
immune system. In contrast to the innate immunity, the adaptive immunity can provide 
specific recognition of antigens, because of a great variability and rearrangement of 
receptor gene segments (Janeway and Medzhitov, 2002; Murphy, 2012). The adaptive 
immune response has two goals: to provide functional effector cells in order to augment 
innate immune response, and to provide immunological memory, capable of mounting a 
quicker and more robust response to the same pathogen upon a second encounter 
(Hamilton and Jameson, 2007). The adaptive immune system is composed of B and T 
lymphocytes (Iwasaki and Medzhitov, 2010). B cells produce antibodies that destroy 
extracellular microorganisms in order to prevent intracellular infections, whereas T 
cells recognize intracellular antigens, generated either from extracellular antigens 
ingested by other cells or from proteins in situ. T cells are able to directly kill the cell 
infected with intracellular pathogens such as viruses, or to “help” in response to 
extracellular pathogens by interacting with B cells (Murphy, 2012). 
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1.2 T cell-mediated immunity 
T cells initiate and regulate adaptive immunity to infections and cancer and play an 
important role in autoimmunity, allergy and transplantation. T cell function relies on 
binding of the T cell receptor (TCR) to antigens, which are short peptides presented on 
major histocompatibility complex (MHC) molecules on the surface of antigen-
presenting cell (APC) (Lever et al., 2014).  
CD8 T cells are the key effector cells of the adaptive immune system. Upon antigen 
encounter, they differentiate into mature cytotoxic T lymphocytes (CTLs) that then kill 
antigen-bearing target cells (Parish and Kaech, 2009). CTL responses are necessary to 
control variety of bacterial and viral infections. They migrate to the site of infection and 
specifically target the infected cells (Williams and Bevan, 2007). 
CD4 T cells are crucially involved in immune responses. They regulate macrophage 
function, help B cells to produce antibodies, enhance and control CD8 T cell responses, 
arrange immune responses against diversity of pathogens. In addition, CD4 T cells 
regulate suppression to control autoimmunity and to adjust magnitude and persistence 
of the infection (Zhu et al., 2010). Importantly, CD4 T cells are key components of 
immunological memory. Without the help of CD4 T cells, the generation of B cell 
memory and the maintenance and secondary expansion of memory CD8 T cells are 
impaired (Tokoyoda et al., 2009; Sun and Bevan, 2003; Sun et al., 2004). 
 
1.2.1 Antigen presentation 
Naïve T cells recirculate between the lymph nodes, blood and spleen. They do not 
directly encounter antigens in the periphery but rely on professional APCs, mostly DCs, 
but also B cells and macrophages that present antigens to T cells (Heath and Carbone, 
2001). DCs are located in lymphoid and non-lymphoid peripheral tissue where they 
constitutively sample the microenvironment and phagocytose microbial products and 
apoptotic cells. In most tissues, DCs are present in an immature state. At sites of 
infection they take up pathogens, leading to activation of their Toll-like receptors 
(TLRs), and become mature. Mature DCs show increased expression of MHC class I 
(MHC I) and class II (MHC II) molecules and co-stimulatory molecules, which enable 
them to prime T cells. During infection, tissue antigen-bearing DCs acquire migratory 
properties and travel into draining lymph nodes, where antigen presentation to T cells 
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occur (Arens and Schoenberger, 2010; Mellman and Steinman, 2001; Murphy, 2012). 
Recognition of antigens, which are presented to specific T cell receptors (TCRs) on MHC 
molecules of APCs, is crucial for T cell activation. CD8 T cells recognize protein-derived 
peptides on MHC I, whereas CD4 T cells recognize peptides bound to MHC II (Vyas et al., 
2008; Blum et al., 2013; Lever et al., 2014). These peptides have a different origin: MHC 
I molecules present endogenous (cytosolic) antigens, whereas MHC II molecules present 
exogenous antigens. Interestingly, exogenous antigens can be presented on MHC I 
molecules, in a process called cross-presentation, which is crucial for the initiation of 
immune response against viruses that do not infect APCs (Neefjes et al., 2011). 
Furthermore, under non-inflammatory self-antigens are also cross-presented, however 
this leads to deletion of self-reactive CTLs in a process called cross-tolerance (Kurts et 
al., 2010). 
 
1.2.2 The immunological synapse 
1.2.2.1 Structural diversity 
Recognition of antigens is a physical process that requires formation of a cell-cell 
junction between T cells and APCs. This interaction takes place through the formation of 
a specific structure at the interface: immunological synapse (IS) (Depoil and Dustin, 
2014; Yokosuka et al., 2005). The IS was originally described to be formed between T 
cells and B cells or T cells and planar bilayers. Confocal microscopy revealed that the 
structure of the IS consists of two rings of molecules, which were named 
supramolecular activation clusters (SMAC) (Monks et al., 1998; Grakoui et al., 1999; 
Alarcon et al., 2011). The central SMAC (cSMAC) includes TCR-pMHC interactions 
together with the signaling molecule protein kinase C (PKC-θ), whereas adhesion 
molecule interactions, between lymphocyte function-associated antigen (LFA-1) and 
ICAM-I, surround the cSMAC and form the peripheral SMAC (pSMAC) (Monks et al., 
1998; Thauland and Parker, 2010). This IS has a typical bull’s-eye pattern and is called a 
classical IS (Fig. 1A). Further studies showed that there is a more peripheral region than 
pSMAC, called distal SMAC (dSMAC) containing large molecules like CD43 and CD45, 
which are firstly recruited to the cSMAC but later translocate to the dSMAC (Alarcon et 
al., 2011; Delon et al., 2001; Allenspach et al., 2001; Freiberg et al., 2002; Saito and 
Yokosuka, 2006).  
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Apart from the bull’s-eye classical type, other non-classical IS forms have been 
identified: the multifocal synapse and the kinapse. The multifocal synapse is 
characterized by small TCR-pMHC interaction clusters at the T cell:APC interface, in 
contrast to classical IS where they are concentrated in the center of the interface (Fig. 
1B). The kinapse is formed between two motile cells and is characterized by crescent-
shaped accumulation of LFA-1-ICAM-1 in the middle of the cell (lamella) pointing 
towards the direction of migration, whereas TCR-pMHC clusters accumulate in trailing 
uropod (Fig. 1C) (Thauland and Parker, 2010). 
 
 
 
Figure 1. Immunological synapse structures 
A: Bull’s eye-classical IS. B: Multifocal IS. C: Immunological kinapse. TCR-pMHC and LFA-1-ICAM 
interactions are shown in green and red, respectively (Thauland and Parker, 2010; modified). 
 
Why does the IS structure show such diversity? Firstly, the T cell differentiation state 
has a profound effect on IS structure (Thauland and Parker, 2010). Double-positive (DP) 
thymocytes interacting with either thymic epithelial cells or planar bilayers form a 
multifocal synapse, whereas mature T cells form classical IS. Thus, it was suggested that 
low TCR expression in immature thymocytes regulates synapse formation (Hailman et 
al., 2002; Lee et al., 2003). Furthermore, it is suggested that apart from TCR signal 
strength also other conditions play here a role in the IS formation, like antigen dosage 
(Thauland and Parker, 2010). For instance, type 1 and type 2 T helper cells (Th1 and 
Th2) cells form different IS type with planar bilayers. Th2 cells usually form a multifocal 
IS, however at decreased antigen dosage, the pMHC-TCR interactions are located in the 
center. Interestingly, ICAM-LFA-1 did not form a pSMAC in this case. In contrast, Th1 
cells did not change IS structure with decreasing antigen concentration (Thauland et al., 
Introduction 
 
6 
 
2008). Thus, IS synapse formation does not always depend on TCR signal strength, 
because T cell differentiation state plays here also an important role. 
Secondly, the type of APC can affect IS structure. Interaction between DC and naïve CD4, 
CD8 and activated CD4 T cell results in multifocal synapse formation (Brossard et al., 
2005; Fisher et al., 2008; Alarcon et al., 2011). In contrast, interaction of CD4 T cells 
with B cells results in a formation of a central ring rich in TCR-pMHC clusters 
surrounded by the ring of adhesion molecules (Grakoui et al., 1999; Yuseff et al., 2013; 
Duchez et al., 2011).  
Furthermore, it is suggested that the IS is formed for function. The classical bull’s eye IS 
is formed mostly by CTLs and Th1 cells, thought to facilitate the directed release of 
effector cytokines and cytolytic granules (Thauland et al., 2008; Stinchcombe and 
Griffiths, 2003). In contrast, the classical IS is not required for thymic selection, T-cell 
priming or Th2 function, at least under some conditions, suggesting that IS structure is 
linked to the function (Thauland and Parker, 2010). 
 
1.2.2.2 Function of immunological synapse 
The IS can be considered to have three functional layers, depending on receptor 
interactions, signal transduction and cytoskeletal transport. 
The receptor interaction layer includes TCRs, adhesion molecules, co-stimulatory and 
co-inhibitory molecules, and co-receptors (Dustin and Depoil, 2011). TCR-CD3 
microclusters are formed at the initial contact site with pMHC, as early as 5 seconds. 
After 1-2 min T cells expand the contact area, more microclusters are formed and 
accumulate at the periphery (expansion phase) and after reaching a maximum of cell 
spreading they move toward a center and create cSMAC after 5 min (Yokosuka et al., 
2005; Campi et al., 2005). Adhesion molecules are important components of the 
receptor interaction layer. LFA-1 is essential for IS formation, because its engagement of 
ICAM-1 facilitates TCR-pMHC interactions. The co-stimulatory (CD28-CD80/86) and co-
inhibitory (CTLA-4-CD80/86 and PD-1-PD-L1) complexes are located at the TCR 
microcluster where they modulate the TCR signal in order to increase or decrease the T 
cell activation (Tseng et al., 2008; Fooksman et al., 2010; Pentcheva-Hoang et al., 2004; 
Yokosuka et al., 2012).  
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The signaling layer contains lymphocyte-specific protein tyrosine kinase (Lck), non-
receptor tyrosine kinase ζ-associated protein of 70 kDa (ZAP-70), phospolipase Cγ 
(PLCγ) and protein kinase (PKCθ). Although the TCR has no intrinsic catalytic activity, it 
forms a multisubunit complex with CD3, containing immunoreceptor tyrosine-based 
activation motifs (ITAMs). Upon antigen recognition, the tyrosine kinase Lck 
phosphorylates ITAMs. Further, ZAP-70 is recruited and phosphorylates several 
adaptor proteins, such as the linker for activation of T cells (LAT) and Src homology 2 
(SH2) domain-containing leukocyte phosphoprotein of 76 kDa (SLP-76). 
Phosphorylation of LAT is essential for PLCγ activation and increases the level of 
intracellular Ca2+ (Dustin and Depoil, 2011; Saito and Yokosuka, 2006; Yokosuka et al., 
2005). The initiation of TCR signaling takes place in the microcluster of the d- and 
pSMAC, whereas signal termination and TCR degradation take place in the cSMAC. 
Moreover, it has been shown that a member of the endosomal sorting complex required 
for transport (ESCRT) of proteins, TSG-101 is required for cSMAC formation and 
dephosphorylation of TCR signaling (Lee et al., 2003; Varma et al., 2006; Fooksmann et 
al., 2010; Vardhana et al., 2010). The signaling layer is integrated within cytoskeletal 
layer to this extent that adhesion and TCR signaling events require filamentous actin (F-
actin) polarization and reorganization (Dustin and Depoil, 2011). 
The cytoskeletal layer is assembled around three filament-forming proteins: actin, 
myosin II and tubulin (Dustin and Depoil, 2011). Actin polarization is not only crucial 
for microcluster transport but also for the tyrosine phosphorylation events within the 
clusters leading to sustained Ca2+ signaling. Myosin IIA activity maintains the radial 
symmetry and overall organization of IS (Babich et al., 2012), whereas the microtubule 
network position microtubule organization center (MTOC) organizes the alignment of 
secretory organelles in the IS enabling direct release of cytokines toward the APC (Huse, 
2012). 
 
1.2.3 T cell activation 
To be effectively activated T cells require three signals: signal 1, 2 and 3. Signal 1 
(antigen recognition) is mediated by binding of peptide MHC (pMHC) to a specific TCR. 
The most proximal event is the tyrosine phosphorylation of ITAMs (described in detail 
in 1.2.2.2), followed by the activation of several signaling pathways. Signal 2 (co-
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stimulation) is mediated mostly by binding of CD28 on naïve T cells with CD80/86 on 
APCs. Together, TCR engagement and co-stimulation lead to T cell activation, expansion 
and acquisition of effector function. When only signal 1 is delivered, T cells become 
anergic, therefore signal 1 and 2 are required for T cell activation. For the full activation, 
T cells need signal 3, the production of cytokines by APCs at distinct stages of a T cell 
response. The particular cytokine combination will then drive the T cell differentiation 
to specific types of effector cells (Lichtenstein et al., 2012; Goral, 2011). 
Upon specific antigen recognition, naïve CD4 T cells develop into T helper (Th) cells, 
classified into Th1, Th2 and Th17. Th1 and Th17 control inflammatory responses, 
effective for anti-viral and anti-bacterial immunity, whereas Th2 cells control antibody 
responses required for anti-viral and anti-parasitic immunity (Lichtenstein et al., 2012).  
Signal 3 plays the central role in fate determination of Th cells. Th1 cells develop in the 
presence of interleukin 12 (IL-12) and interferon-gamma (IFNγ), Th2 cells develop in 
the presence of IL-2 and IL-4 and Th17 differentiate in the presence of transforming 
growth factor-beta (TGF-β), IL-6 and IL-21 (Zhu et al., 2010). 
Encounter of antigen by naïve CD8 T cells leads to their expansion and differentiation 
into effector CTLs, which kill target cells. Following the clearance of the infection, most 
(>90%) of the antigen-specific CD8 T cells die by apoptosis and only a few cells survive 
as long-lived memory T cells (Kaech et al., 2002; Boyman and Sprent, 2012). It has been 
shown that type I interferons (IFN-α/β) and IL-12 play an important role in the 
differentiation of effector CD8 T cells upon infection. IFN-α/β promote DC maturation 
and their ability to cross-prime CD8 T cells. In addition, IFN-α promotes clonal 
expansion and IFNγ production by CD8 T cells. Importantly, in the presence of IFN-α/β 
and IL-12 CD8 T cells upregulate mRNA expression of the effector proteins granzyme B 
and perforin, which are important for the killing of target cells (Curstinger et al., 2005). 
 
1.2.4 T cell tolerance 
The immune system is balanced between self-antigen-driven tolerance and pathogen-
driven immunity. A shift towards extreme ends of both, i.e., lack of response 
(immunodeficiency) or an inappropriate, excessive response (autoimmunity or allergy), 
leads to pathophysiology. Self-tolerance is maintained firstly by the development and 
selection of T cells in the thymus (central tolerance) and secondly by suppression, 
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deletion and anergy of mature T cells in the nonlymphoid and lymphoid organs 
(peripheral tolerance) (Kyewski and Klein, 2006). 
 
 
1.2.4.1 Central tolerance 
Elimination of autoreactive T cells in the thymus is an important part of T cell 
development to avoid the potentially pathological state of autoimmunity. Subsequent to 
positive selection and CD4 and CD8 T cell commitment, thymocytes translocate to the 
thymic medulla, where negative selection occurs. Expression of tissue-restricted 
antigens (TRAs) on medullary thymic epithelial cells (mTECs) plays an essential role in 
central tolerance: TRAs represent virtually all parenchymal organs, thereby mirroring 
peripheral-self. TRAs are directly presented by mTECs or cross-presented by thymic 
DCs to the thymocytes (Anderson, 2002; Redmond and Shermann, 2005; Klein et al., 
2009; Hogquist et al., 2005). If the recognition of these antigens on MHC complexes is 
too strong, those autoreactive thymocytes will be negatively selected and die by 
apoptosis (Venanzi et al., 2004). The transcription factor AIRE (autoimmune regulator) 
plays an important role in turning on TRAs and its mutation or absence leads to 
autoimmune disorders (Metzger and Anderson, 2011; Peterson, 2008).  
Despite central tolerance effectiveness, other tolerance mechanisms are required for 
self-reactive T cell silencing because many self-antigens may not access the thymus or 
are expressed at insufficient levels for thymocytes with low-avidity TCR to being 
recognized. Moreover, the human body is constant exposed to the nonpathogenic 
antigens both from the environment and diet to which it should remain tolerant 
(Steinman and Nussenzweig, 2002; Redmond and Shermann, 2005). 
 
1.2.4.2. Peripheral tolerance 
As thymic selection is not a perfect process many low-avidity, autoreactive T cells can 
be found in the periphery. To control these cells in the periphery, tolerance is achieved 
by various mechanisms including clonal ignorance, anergy and clonal deletion (Parish 
and Heath, 2008; Srinivasan and Frauwirth, 2009). 
Immunological ignorance occurs when antigens do not enter lymphoid organs at 
sufficient levels and thereby can not induce an efficient immune response or when 
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antigens are located in privileged sites, such as the central nervous system or the eye, to 
which T cells do not have access (Ochsenbein et al., 1999; Ohashi, 1991; Srinivasan and 
Frauwirth, 2009). Furthermore, tolerance due to ignorance may occur in low-avidity T 
cells because the TCR/MHC affinity needed for T cell activation in the periphery is 
higher than in the thymus. Therefore, such low-avidity self-reactive naïve T cells 
interacting with self-pMHC will not be activated (Parish and Heath, 2008; Srinivasan 
and Frauwirth, 2009; Mescher et al., 2007).  
As described above (see 1.2.1), mature DCs drive immunity, whereas immature DCs 
induce tolerance. The mechanism of T cell tolerance induced by immature DCs involves 
programmed cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) (co-
inhibitory molecules are described in detail in 1.3.2). Thus, CD8 T cells lacking PD-1 and 
CTLA-4 are primed but not tolerized by immature DCs (Probst et al., 2005).  
Anergic T cells are antigen experienced and remain alive for an extended period of time. 
However, they neither proliferate nor produce IL-2 upon restimulation (Lutz and 
Schuler, 2002; Schwartz, 2003; Srinivasan and Frauwirth, 2009). Gene expression 
analysis revealed that PD-1 upregulation is important for induction of both anergy and 
deletion. Furthermore, autoreactive T cells undergoing deletion are characterized by 
excessive upregulatation of the proapoptotic BH3-only Bcl-2 family member Bim and 
downregulation of the anti-apoptotic Bcl-2 family proteins, granzyme B (GzmB), Ly6C 
and the IL-7α chain (Parish et al., 2009; Davey, 2002). Why do some autoreactive T cells 
become anergic and why are others deleted? There is evidence that strength of TCR-
pMHC interaction can play a role. Some studies show that the continuous exposure of a 
clonal T cell line to high versus low doses of antigen induced anergy or deletion, 
respectively (Redmond and Shermann, 2005; Redmond et al., 2005).  
Apart from anergy and deletion, additional tolerance mechanisms exist, which are 
mediated by CD4+CD25+Foxp3+ T cells, called T regulatory cells (Tregs). Natural Tregs 
(nTregs) originate in the thymus during thymocytes maturation, whereas induced Tregs 
(iTregs) develop in secondary lymphoid organs from peripheral naïve CD4+CD25- T 
cells upon antigen stimulation by DCs. iTreg generation occurs mainly in bacterial or 
viral infection, in tumors or in mucosal tissues in the context of oral tolerance 
(Sakaguchi et al., 2009; Tang and Bluestone, 2008; Piccirillo and Shevach, 2004; Bilate 
and Lafaille, 2012; Goldstein et al., 2013). Tregs suppress proliferation of naïve T cells, 
their differentiation into effector cells and cytokine production via cell-cell contact or 
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production of anti-inflammatory cytokines. Thus, interaction of Tregs with DCs causes 
down modulation of their function (downregulation of CD80/86 expression and 
production of proinflammatory IL-6 and TNFα) (Sakaguchi et al., 2008; Belkaid and 
Tarbel, 2009; Sakaguchi et al., 2009). Furthermore, it is reported that IL-10 and TGFβ 
produced by Tregs control colitis and inhibits differentiation of activated T cells to Th1 
or Th2 effector cells, respectively (Liu et al., 2003; Schmitt et al., 2012; Chaudhry et al., 
2011; Wan and Flavell, 2007).  
 
1.3. The role of B7-CD28 superfamily in T cell activation and tolerance 
Interaction of co-signaling molecules between T cells and APCs is an early event for 
transmitting signals to control T cell growth, differentiation, activation and tolerance 
(Tsushima et al., 2007). Function of co-signaling molecules entirely depends on TCR 
signals (signal 1). Co-stimulators enhance TCR-mediated responses, whereas co-
inhibitors inhibit TCR-mediated responses (Chen, 2004). In the absence of sufficient 
TCR signaling, co-signaling molecules lose their function or function aberrantly. 
Following antigen recognition, they are one of the earliest responding elements of the 
immune system. These molecules are members of the immunoglobin and tumor-
necrosis factor (TNF) superfamilies (Chen, 2004). The B7-CD28 superfamily is crucial in 
regulating activation and tolerance of T cells (Sharpe and Freeman, 2002). 
 
1.3.1 Co-stimulatory molecules  
1.3.1.1 CD28 
CD28 is constitutively expressed on the surface of naive CD4 and CD8 T cells and plays a 
major role in co-stimulation in the initial activation of T cells. Engagement of the TCR 
and CD28 ligation results in initiation of T-cell–mediated immunity (Gardner et al., 
2014). CD28 interacts with two ligands on APC: B7-1 (CD80) and B7-2 (CD86), 
providing co-stimulatory signaling. In contrast, CD80 and CD86 ligation with CTLA-4 
provides co-inhibitory signaling (see 1.3.2.1). CD86 is constitutively expressed at low 
levels on DC and upregulated rapidly upon activation, whereas CD80 expression is 
induced later after activation. Both CD80 and CD86 are crucial in regulating T cell 
activation and tolerance (Sharpe and Freeman, 2002; Sotomayor et al., 1999). Binding 
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of CD80/CD86 to CD28 leads to association of phosphatidylinositol 3-kinase (PI3K) and 
its phosphorylation, further inducing IL-2 mRNA production and enhanced T cell 
survival (Rudd et al., 2009; Sharpe and Freeman, 2002). The main function of CD28 co-
stimulation is to augment and sustain T-cell responses initiated by antigen-receptor 
signaling, by promoting T cell survival and therefore enabling cytokines to initiate T-cell 
differentiation and expansion (Sharpe and Freeman, 2002).  
 
1.3.2 Co-inhibitory molecules 
1.3.2.1 CTLA-4  
CTLA-4 (cytotoxic T lymphocyte antigen 4) engagement of CD80/CD86 delivers 
negative signal, which inhibits TCR- and CD28-mediated signal transduction (Sharpe 
and Freeman, 2002). In contrast to CD28, CTLA-4 is expressed at low levels on naive T 
cells, but rapidly upregulated after activation. If the interaction between CTLA-4 and 
CD80/86 is blocked, it will result in enhancement of T-cell responses against foreign- 
and self-antigens. T cells deficient for CTLA-4 show greater cell expansion and cytokine 
production after adoptive transfer into wild-type mice. In addition, CTLA-4-deficient 
mice spontaneously develop CD28-dependent autoimmune responses, which indicates 
that CD28 co-stimulation is actively suppressed by CTLA-4 (Chen, 2004; Sharpe and 
Freeman, 2002). Furthermore, in vivo CTLA-4 blockade with monoclonal antibodies 
confirmed its inhibitory function of T cell responses and the role in augmenting 
antitumor immunity (Sotomayor et al., 1999; Leach et al., 1996; Sharpe and Freeman, 
2002). Interestingly, recent studies revealed that CTLA-4 acts as an inhibitor on 
CD4+CD25+ T cells via transendocytosis of CD80 and CD86. In this way, CTLA-4 
promotes removal and degradation of CD80/CD86 from the APC, preventing access of 
CD28 to its ligands (Gardner et al., 2014; Quereshi et al., 2011). 
 
1.3.2.2 PD-1 
PD-1 (programmed cell death 1) acts as a co-inhibitory receptor during B- and T-cell 
responses. It was first cloned from a T cell hybridoma undergoing programmed cell 
death (Chen, 2004). PD-1 is induced on activated CD4+ and CD8+ T cell, B cells and 
monocytes (Chen 2004; Greenwald et al., 2005). Interestingly, PD-1 is upregulated in 
CD8 T cells interacting with liver sinusoidal endothelial cells (LSECs), which is 
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correlated with PD-L1 upregulation in LSECs, inducing a unique quiescent state in CD8 
T cells (in details described in 1.4.3). 
PD-1 is monomeric and its cytoplasmic domain has two tyrosines: one constitutes an 
immunoreceptor tyrosine-based inhibition motif (ITIM), and the other an 
immunoreceptor tyrosine- based switch motif (ITSM) (Chen 2004; Greenwald et al., 
2005). It is suggested that PD-1 phosphorylation of the cytoplasmic tyrosine domain of 
PD-1 recruits SRC homology 2 (SH2)-domain-containing protein tyrosine phosphatase 
(SHP-2). SHP-2 then dephosphorylates TCR associated CD3ζ and ZAP-70 resulting in 
inhibition of downstream signaling (Dai et al., 2014). This leads to the attenuation of the 
PI3K and Akt pathways, resulting in decreased proliferation, survival and IL-2 
production (Francisco et al., 2010). PD-1 blockade by antibody treatment results in 
rapid expansion of antigen-specific CD8 T cells and improves their effector function 
upon viral infection (Velu et al., 2009). Furthermore, PD-1 blockade inhibits tumor 
growth by enhanced recruitment and proliferation of effector T cells at the tumor sites 
(Iwai et al., 2004). PD-1-deficient mice spontaneously develop lupus-like proliferative 
arthritis and glomerulonephritis with IgG deposition (C57BL/6 background) and 
autoimmune dilated cardiomyopathy or sudden death by congestive heart failure 
(BALB/c background). Moreover, these mice have a high serum titer of IgG 
autoantibodies specific for cardiac troponin I protein, indicating the role of PD-1 in the 
maintenance of peripheral tolerance (Chen, 2004).  
Importantly, PD-1 is highly expressed on exhausted CD8 T cells upon chronic LCMV 
infection as well as upon infection with the human immunodeficiency virus (HIV) 
(Barber et al., 2006, Day et al., 2006). In addition, PD-1 expression observed in HIV-
specific CD8 T cells predicts disease progression, thus it correlates positively with viral 
load (Day et al., 2006). Blocking the interaction of PD-1 with its ligand by administration 
of blocking antibodies can restore the ability of exhausted CD8 T cell to proliferate and 
produce cytokines (Barber et al., 2006; Petrovas et al., 2006; Freeman et al., 2006). PD-1 
is highly induced on tumor infiltrating and circulating tumor-specific T cells and inhibits 
their activation and tumor cell killing (Ji et al., 2015). Checkpoint inhibitors are a novel 
cancer therapy that targets these inhibitory signals and augument antitumor T cell 
responses. Both, PD-1 and CTLA-4 checkpoint inhibitors are lately approved agents in 
melanoma and lung cancer therapy (Brahmer and Pardoll, 2013; Pennock and Chow, 
2015).  
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1.3.2.3 PD-L1 
PD-ligand 1 (PD-L1, also known as B7H1) and PD-ligand 2 (PD-L2) are ligands for PD-1. 
Within the immune system, PD-L1 expression is mostly restricted to macrophages, 
activated B cells, activated T cells and mature DCs. Furthermore, it can be found on the 
surface of nonhematopoietic cells including microvascular endothelial cells and 
nonlymphoid organs like heart, lung, pancreas, muscle and placenta (Greenwald, 2005; 
Bazhin et al., 2014). PD-L1 is also expressed on liver sinusoidal endothelial cells, where 
it plays a pivotal role in LSEC-CD8 T cell priming (see 1.4.3). Importantly, PD-L1 mRNA 
can be found in various human tissues but abundance of mRNA does not correlate with 
protein expression. Experimental evidence showed that PD-L1 can act as co-stimulatory 
and co-inhibitory molecule (Chen, 2004). On one hand, application of blocking 
monoclonal PD-L1 antibodies prevented development of experimental colitis in mice in 
association with decreased expansion of pathogenic T cells, indicating a co-stimulatory 
function of PD-L1 (Kanai et al., 2003). On the other hand, it increased the incidence of 
autoimmune diabetes in non-obese diabetic (NOD) mice and hapten-induced 
hyperreactivity, indicating co-inhibitory function (Chen, 2004). Recent studies 
characterize in detail the influence of PD-L1 deficiency in vivo. In PD-L1-deficient mice 
NK, NKT cells and Gr1+CD11b+ myeloid cells are decreased. Moreover, the percentages 
of pDCs but not cDCs are increased in PD-L1-deficient mice. In the T-cell compartment 
PD-L1 deficiency resulted in an increased amount of Tregs and a decreased amount of 
conventional CD4 T cells (T conv), however, which showed an increase in percentages 
of activated T cells, suggesting that in the absence of PD-L1 the immune system tries to 
maintain its stimulatory/suppressory balance by engaging more Tregs (Bazhin et al., 
2014). 
 
1.3.2.4 PD-L1/PD-1 inhibitory pathway  
The PD-L1/PD-1 pathway controls the balance between peripheral tolerance and 
immunity in several ways. PD-L1/PD-1 interactions inhibit the expansion of naïve self-
reactive T cells and/or their differentiation into effector cells (Francisco et al., 2010). It 
has been shown that peripheral CD8 T cell tolerance depends on PD-1 signals, as the 
absence of PD-1 resulted in conversion of tolerance into priming induced by resting DCs 
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upon LCMV infection (Probst et al., 2005). Moreover, tissue-specific expression of PD-L1 
has a key role in protection against self-reactive T cells within pancreas and inhibits 
development of autoimmune diabetes (Keir et al., 2006). Endothelial antigen 
presentation to CD8 T cells is an important step in the pathogenesis of allograft 
rejection and can be involved in organ-specific autoimmunity as PD-L1 expression is 
induced on human and mouse endothelial cells inhibiting CD8 T cell effector responses 
to endothelial antigen presentation (Rodig et al., 2003). Taken together, PD-L1/PD-1 
interactions play an important role in the induction of tissue tolerance. 
PD-L1 expression is also induced on LSECs. Priming of naïve CD8 T cells by LSECs leads 
to development of antigen-experienced CD8 T cells that are unable to perform effector 
functions (Limmer et al., 2000). Interestingly, this LSEC-mediated unresponsiveness of 
CD8 T cells is PD-1/PD-L1 dependent (Diehl et al., 2008) and requires the integration of 
co-inhibitory signaling over time (Kaczmarek et al., 2014). 
The PD-L1/PD-1 pathway plays an important role in exhaustion of CD8 T cells. These 
cells are generated under chronic antigen stimulus and express activation/memory 
markers (CD44high CD62Llo), however they are unable to perform effector functions 
(Zajac et al., 1998). Interestingly, studies investigating CD8 T cell responses upon 
chronic LCMV and HIV infection revealed that exhausted CD8 T cells strongly 
upregulate PD-1 and the blockade of the PD-L1/PD-1 pathway had a beneficial effect on 
antigen-specific impaired CD8 T cells, restoring their ability to proliferate, to produce 
cytokines and to perform cytotoxic activity (Barber et al., 2006; Petrovas et al., 2006; 
Freeman et al., 2006). Therefore, these findings indicate the PD-1/PD-L1 pathway as a 
therapeutic target to augment not only the immune responses during chronic viral 
infections. Importantly, PD-1 checkpoint pathway is the target in the novel 
immunotherapy (as mentioned in 1.3.2.3). 
 
1.4 Liver as immunological organ 
The liver is an organ that fulfills diverse functions in the metabolism of carbohydrates, 
proteins and lipids. Moreover, it plays an important role in the clearance of toxins and 
pathogens. Unique hepatic regulatory mechanisms prevent induction of immunity 
against antigens from gastrointestinal duct, damaged cells and neo-antigens that arise 
during metabolic processes. Although most of the pathogens reaching the liver via the 
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blood are cleared, certain pathogens like Plasmodium spp sporozites, causing malaria, 
hepatitis B and C virus have evolved multiple strategies to escape the T cell-mediated 
immunity and to establish hepatic infection (Thompson and Knolle, 2010; Protzer et al., 
2012; Knolle and Thimme, 2014). The tolerogenic properties of the liver are exemplified 
by its role in oral tolerance, the immunological mechanism whereby the mucosal 
immune system maintains unresponsiveness to antigens that might induce undesired 
immune responses, and portal venous tolerance, the induction of the peripheral 
tolerance following portal vein delivery of antigen. Furthermore, the liver exemplifies 
its tolerogenic properties by the persistence of infections and tumor metastases, as well 
as by immune tolerance against hepatic transplants (Crispe, 2003; Thomson and Knolle, 
2010). 
 
1.4.1 Liver microarchitecture 
Blood is delivered to the liver via the portal vein, which is enriched in nutrients and 
bacterial degradation products, and via the hepatic artery, which also supplies large 
amounts of blood continuously to the liver (Knolle and Thimme, 2014). About 30% of 
the total blood passes through the liver every minute and it carries about 108 
lymphocytes in 24 hours (Racanelli and Rehermann, 2006). In Figure 2, the schematic 
overview of the hepatic microarchitecture is shown. Hepatocytes are separated from 
the blood stream by LSECs. The slow blood flow within and the narrow diameter of 
hepatic sinusoid facilitates the interaction of lymphocytes with LSEC, the main antigen 
presenting cells in the liver, and promotes lymphocytes extravasation (Racanelli and 
Rehermann, 2006; Knolle and Thimme, 2014). The space of Disse, located between 
LSECs and hepatocytes, is filled with extracellular matrix and is populated with stellate 
cells (HSC), which are immune-sensing cells involved in liver fibrosis (Protzer et al., 
2012). Blood plasma passes from the sinusoids into the space of Disse, where lymph is 
collected and flows through lymphatic vessels further into portal tracts to the draining 
lymph nodes. In contrast to LSECs, hepatocytes have no direct contact to the blood flow 
but they can directly interact with T cells via LSEC fenestrations (Knolle and Thimme, 
2014; Crispe, 2003). 
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Figure 2. Schematic overview of  liver microarchitecture. 
LSECs line the liver sinusoids and together with stellate cells separate hepatocytes from blood passing 
through the liver (adapted from Knolle and Thimme, 2014). 
 
1.4.2 Antigen-presenting cells in the liver 
Liver dendritic cells 
Liver DCs are located around central veins and portal tracts and can be divided into 
myeloid DCs (mDCs) (CD11c+CD8α-CD11b+), CD8α+ DCs (CD11c+CD8α+CD11b-) and 
plasmocytoid DCs (pDCs) (CD11clowB220+Ly6C+CD11b-SIGLECH+). Immature DCs 
express the CC-chemokine receptor 1 (CCR1) and CCR5 and are recruited into the liver 
via interaction with Kupffer cells expressing CC-chemokine ligand 3 (CCL3). After 
maturation DCs lose CCR1 and CCR5 expression and upregulate CCR7, with which they 
gain responsiveness to CCL19 and CCL21 produced by lymphoid tissue. Murine liver 
bulk DCs or purified mDCs are less mature, in phenotype and function, than lymphoid 
tissue DCs. They express MHC II at lower levels, secrete less IL-12 and preferentially 
produce IL-10 and IL-27. Freshly isolated liver mDCs are tolerant to lipopolysaccharide 
(LPS), called „endotoxin tolerance“. Also liver pDCs express low levels of MHC class II 
molecules and CD40, CD80 and CD86. In response to microbial TLR stimulation, they 
produce less IFNα, IL-6, IL-12 and TNF than splenic pDCs. It is suggested that pDCs 
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modulate T cell responses by expression of PD-L1, production of IL-10 and induction of 
T cell apoptosis (Thompson and Knolle, 2010; Racanelli and Rehermann, 2006; Crispe, 
2003). 
 
Kupffer cells 
Kupffer cells are resident macrophages in the liver and represent the largest 
macrophage population in the body. They can be derived from circulating monocytes or 
develop from yolk sac-derived cells, the precursors in organs (Racanelli and 
Rehermann, 2006; Knolle and Thimme, 2014). Their location in hepatic sinusoids 
enables them to interact with circulating T cells, NK and NKT cells. Kupffer cells are the 
dominant hepatic APC population that presents lipid antigens in a CD1d-restricted 
manner to NKT cells. Moreover, they express the high-affinity Fc receptor for IgA and 
complement receptors with which they can efficiently remove the complement-coated 
bacteria. Kupfer cells can exert both immunogenic and tolerogenic function: they are 
involved in tolerance against soluble antigens and liver transplants and can stimulate 
the suppressive activity of Treg cells. In contrast, in Leishmania donovani-induced 
granulomas and Borrelia burgdorferi infection, Kupffer cells induce immunity by cross-
presentating parasite antigens to CD8 T cells and lipid antigens to NKT cells, 
respectively (Crispe 2003, Thompson and Knolle, 2010, Knolle and Thimme, 2014). 
 
Hepatocytes 
Although hepatocytes are separated from the blood stream by LSECs, stellate cells and 
Kupffer cells, they can directly present antigens to CD4 and CD8 T cells through LSEC 
fenestration. Although they express only low levels of MHC class I molecules, they are 
able to activate CD8 T cells. However, first antigen contact with hepatocytes induces T 
cell tolerance via clonal deletion, in contrast, when T cells first encounter antigen in 
lymphoid tissue, reencounter of the antigen on hepatocytes can cause immune-
mediated hepatitis. Additionally, the CD1-restricted activation of natural killer T (NKT) 
cells by hepatocytes leads to the generation of IL-10-expressing CD8 T cells with 
regulatory function (Thompson and Knolle, 2010; Knolle and Thimme, 2014). 
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Liver sinusoidal endothelial cells 
Apart from hepatocytes, LSECs are the most abundant cell type in the liver. Together 
they account for about 80% of the liver mass (Kim and Rajagopalan, 2010). In the 
sinusoids, the endothelium is characterized by fenestrations, which measure 
approximately 100 nm in diameter and occur with the frequency of 9-13 per μm2, which 
accounts for approximately 10% of entire LSEC surface (Braet and Wisse, 2002; Knolle 
and Gerken, 2000). However, the passage of gold particles larger than 20 nm is 
prevented by extracellular matrix, inhibiting their free diffusion through fenestrae into 
the space of Disse. This barrier can be overcome by cells squeezing through 
fenestrations or by active transport across LSECs of for instance iron to be delivered to 
hepatocytes (Knolle and Limmer, 2003; Protzer et al., 2012).  
LSECs are resident APCs and express different molecules, which are necessary for the 
interaction with leukocytes (for instance: CD54 and CD106) and several pattern 
recognition receptors (PRRs), which enable recognition of pathogens. The expression of 
PRRs allows them to remove non-enzymatically glycolysed proteins and other harmful 
molecules from the circulation. LSECs can phagocytose material up to 200 nm in size. In 
contrast, Kupffer cells phagocytose larger complexes, leading to a division of labor in 
the clearance of different pathogens. Apart from that, LSECs constitutively express co-
stimulatory CD80, CD86 CD40 and ICOS-L and co-inhibitory PD-L1. Moreover, they 
express MHC class I and class II molecules, which are necessary for antigen presentation 
to CD8 and CD4 T cells, respectively (Knolle and Limmer, 2003; Knolle and Gerken, 
2000; Thompson and Knolle, 2010). 
 
1.4.3 Antigen presentation to CD8 T cells by liver sinusoidal endothelial cells 
LSECs are unique organ-resident APCs in the liver, which combine scavenger activity 
with cross-presentation of exogenous antigens on MHC class I molecules to CD8 T cells 
(Limmer et al., 2005; Diehl et al., 2008). Intravenous injection of Alexa647 -labeled 
ovalbumin (OVA) was followed by its accumulation in hepatic cells (i.e. LSECs), whereas 
little accumulation in spleen or lungs was observed. Direct comparison of LSECs and 
DCs from liver or spleen showed that LSECs are more efficient in taking up and cross-
presenting OVA to H2Kb-OVA specific CD8 T cells. Although the uptake via mannose 
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receptor is essential for cross-presentation in DCs, the mannose does not seem to be 
involved in LSECs (Schurich et al., 2009; Höchst et al., 2012).  
Cross-presentation of antigens to naive CD8 T cells by mature DCs leads to their 
differentiation into CTLs, which produce IL-2 and IFNγ (Kurts, 2010; Cui and Kaech, 
2010; Williams and Bevan, 2007). However, CD8 T cells primed by LSECs develop a 
unique differentiation state. Within 18 hours LSEC-stimulated CD8 T cells upregulate 
activation markers and Granzyme B expression (GzmB), comparable to DC-stimulated 
CD8 T cells (Diehl et al., 2008; Böttcher et al., 2014). However, in contrast to DC-
stimulated T cells, GzmB expression declines within 48 hours back to baseline. 
Interestingly, these GzmB-positive LSEC-stimulated CD8 T cells possess cytotoxic 
function as they killed target cells in an antigen-specific fashion (Böttcher et al., 2014). 
However, longer LSEC stimulation (i.e 3-5 days) under non-inflammatory conditions 
induces non-responsiveness of CD8 T cells, characterized by lack of IL-2 or IFNγ 
production after restimulation (Limmer et al., 2000; Diehl et al., 2008). Importantly, 
CD8 T cell proliferation and expansion within the first 72 hours of LSEC- and DC-
stimulated CD8 T cells is similar, but at later time points LSEC-stimulated T cells do not 
expand to the same extent. LSEC-primed T cells are CD25lowCD44highCD62Lhigh enabling 
them to recirculate through secondary lymphoid organs. The induction of this unique 
functional state in CD8 T cells by LSEC is mediated by co-inhibitory PD-L1, which is 
expressed on LSEC and further induced during contact with CD8 T cells (Diehl et al., 
2008). Priming of CD8 T cells by LSEC does not cause their deletion but instead 
generates an antigen-experienced CD8 T cell population that possesses memory-like 
properties: they can generate recall responses and give rise to effector CTLs that can 
control the infection, indicating that T cell priming by LSECs contributes to 
antipathogen immunity (Diehl et al., 2008; Böttcher et al., 2013).  
 
1.5. Small GTPases 
The organization of many fundamental cellular processes, like intracellular signaling 
and vesicular trafficking, is regulated by small guanine nucleotide-binding proteins of 
the Ras superfamily (Goldberg, 1998; Kolanus, 2007; Gillingham and Munro, 2007).  
All small GTPases share a common biochemical mechanism and act as molecular 
switches (Fig. 3) (Wennerberg et al., 2005). Activation and inactivation of each member 
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is regulated by GTP binding and GTP hydrolysis, respectively, and this process is 
regulated by guanine exchange factors (GEFs) (catalysis of GDP into GTP), and GTPase-
activating proteins (GAPs) (catalysis of GTP hydrolysis) (Donaldson and Jackson, 2011; 
Kolanus, 2007; Wennerberg et al., 2005; Shin and Nakayama; 2004). 
 
 
Figure 3. Schematic GDP-GTP cycle of Arf (Shin and Nakayama, 2004; modified). 
General regulation of Arf activation and inactivation. An inactive form of Arf, GDP-bound, is converted to 
active, GTP-bound, form through GDP-GTP exchange catalyzed by a GEF. Upon interaction of active form 
of Arf with effector molecules, such as coat proteins and lipid kinases, GTP is hydrolyzed to GDP with a 
help of a GAP.  
 
1.5.1 Arf family of small GTPases 
ADP-ribosylation factor (Arf) GTPases are crucial regulators of secretion, endocytosis, 
phagocytosis and signal transduction (Burd et al., 2004). Figure 4 shows the structure of 
Arfs; GDP-GTP cycle changes the conformation of the protein by causing a loop of beta 
sheets between switch regions, called the interswitch, to move away from GTP binding 
site. A distinguishing structural feature of Arfs separating them from other GTPase 
proteins is their N-terminal amphipathic helix, where a myristoyl group, that can 
mediate membrane binding, is attached. The myristoylation of N-terminus results in 
replacement of methionine at the position 2 with glycine. Upon GTP-binding, the 
myristoylated N-terminal amphipathic helix is displaced from hydrophobic pocket and 
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can be inserted into the membrane (Gillingham and Munro, 2007; Donaldson and 
Jackson, 2011). 
 
 
 
 
Figure 4. Schematic structure of Arf protein (Gillingham and Munro, 2007). 
The Arfs have switch regions that change confirmation upon binding of GTP regions. Furthermore, they 
contain N-terminal amphipathic helix, which is often myristoylated. 
 
There are six mammalian ARF proteins, which are divided in three classes: Class I (Arf1, 
Arf2, Arf3), Class II (Arf4 and Arf5) and Class III (Arf6) (Donaldson and Jackson, 2011). 
Arf1 and Arf6 are the most characterized Arf proteins. Arf1 is located at the Golgi 
compartment and mediates transport of the early secretory pathway from Golgi into 
endoplasmic reticulum (ER). In addition, it modulates the Golgi structure by stimulation 
of spectrin and actin skeleton at the Golgi membrane (D’Souza-Schorey and Chavrier, 
2006). Arf6 primarly acts at the plasma membrane. Many studies show its contribution 
in cell spreading, Rac-induced ruffling, cell migration and wound healing (Donaldson, 
2003). Moreover, Arf6-GFP recruits ARNO (cytohesin-2) to the plasma membrane for 
activation of Arf1 and regulates actin remodeling (Cohen et al., 2007; Boshans et al., 
2000). 
 
1.5.2 Small GTPase exchange factors  
Because inactive GDP-bound Arfs are primarily cytosolic, their activation by GEFs is 
crucial for their function in membrane trafficking. Arf-GEFs possess a Sec7 domain, 
which is responsible for their activity and a pleckstrin homology domain (PH), 
important for membrane association and N-terminal coiled-coil domain (CC), which is 
responsible for the interaction with cellular-binding partners. The best-characterized 
Arf-GEFs are the cytohesins. The cytohesin family consists of four members: cytohesin-
1, -2, -3 and -4 (Casanova, 2007; Kolanus, 2007; Shin and Nakayama, 2004).  
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Cytohesin-1 interacts with a β2-integrin (LFA-1), which mediates its activation and GEF 
activity. Moreover, overexpression of cytohesin-1 in Jurkat cells facilitates adhesion of 
LFA-1 to ICAM-1. More detailed studies revealed that cytohesin-1 expression in DCs is 
crucial for β2-integrin adhesion and for bone marrow DC (BMDC) migration into lymph 
nodes in vitro and in vivo (Weber et al., 2001; Quast et al., 2009). Cytohesin-2 interacts 
with Arf6 at the plasma membrane. Although cytohesin-2 and cytohesin-3 are very 
closely related (80% identity) they have different functions in β1 integrin recycling. 
Knockdown of cytohesin-2 causes decrease of cell adhesion, migration and spreading, 
whereas cytohesin-3 knockdown enhances these processes. Additionally, cytohesin-3 
acts upstream of PI3K activity in insulin signaling (Oh and Santy, 2010; Coehn et al., 
2007; Kolanus, 2007). Cytohesin-4 is less characterized than other family members. 
Like other cytohesins, it is not inhibited by Brefeldin A and shows GEF activity with Arf1 
and Arf5 but not with Arf6 (Ogasawara et al., 2000). 
 
1.5.3 Arl4 family 
The Arl4 family consists of Arl4a, Arl4c and Arl4d. They can be distinguished from the 
other members of the Arf family by the C-terminal extension of 10-15 basic residues 
and a short insertion in the loop between the two switch regions. Similar to the Arf 
family, most Arl4s have an N-terminal myristoyl group, which is only exposed in the 
GTP-bound form (Hofmann et al., 2007; Pasqualato et al., 2002). Furthermore, it 
contains a C-terminal nuclear localization signal (NLS) (Lin et al., 2000).  
Arl4a is distributed to the plasma membrane, cytosol and trans-Golgi network (TGN) 
(Lin et al., 2011). Arl4a can regulate actin remodeling via recruitment of cytohesin-2 to 
the plasma membrane and Arf6 activation (Li et al., 2007, Hoffmann et al., 2007). 
However, more recent studies revealed that Arl4a-induced cytoskeletal remodeling is 
Arf6-independent (Patel et al, 2011). Arl4a is the only Arl4 family member that interacts 
with golgin GCC185 in a GTP-dependent manner and recruit CLASPs, a family of 
microtubule binding proteins, to the Golgi membrane (Lin et a., 2011).  
Arl4c, together with Arl4a and Arl4d, can recruit the C-terminal PH domains of 
cytohesin-1, cytohesin-3 and cytohesin-4 to the plasma membrane (Hofmann et al., 
2007). Recent studies showed that expression of Arl4c is induced by stimulation with 
both Wnt3a and epidermal growth factor (EGF) resulting in epithelial tubular structure 
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formation (Matsumoto et al., 2014). The same group suggested that Arl4c could be a 
therapeutic target in lung and colorectal carcinoma, as Arl4s small interfering RNA 
(siRNA) injection inhibited tumor growth (Fujii et al., 2014). 
Arl4d contains an N-terminal myristoylation site, two switch sites and a NLS (Fig. 5). 
 
 
Figure 5. Schematic structure of wild type Arl4d and its mutants (Li et al., 2007). 
Arl4d(T35N) - putative GTP-binding-defective; exist only in inactive form (GDP-bound); 
Arl4d(Q80L) -putative GTP-bound form; exist only in active form (GTP-bound); 
Arl4dΔC - lacks last 16 amino acids (aa) at C-terminus (NLS); no nuclear localization; 
Arl4d(G2A) – N-myristoylation-deficient mutant; no membrane localization. 
 
Human ARL4D interacts with cytohesin-2, particularly ARL4D WT, ARL4D(Q80L) and 
ARL4D(G2A) but not with ARL4D(T35N) or ARL4DΔC, demonstrating that this 
interaction is nucleotide dependent and requires the C-terminal NLS. Similar to other 
GTPases, localization of Arl4d at the plasma membrane is GTP- and myristyolation-
dependent (Li et al., 2007). Furthermore, ARL4D recruits cytohesin-2 to the plasma 
membrane. The C-terminal polybasic c domain and the PH domain of cytohesin-2 are 
necessary for its relocation to the plasma membrane. Interestingly, cytohesin-2 does not 
catalyze nucleotide exchange on ARL4D but on ARF6. More detailed studies revealed 
that ARL4D activates ARF6 through cytohesin-2 that modulates actin remodeling and 
cell migration (Hofmann et al., 2007; Li et al., 2007). 
Valproic acid (VPA) is involved in neuritogenesis and protection of the neurons 
upregulates Arl4d expression and the Arl4d-cytohesin-2-Arf6 signaling unit is involved 
in VPA-dependent neurite growth (Yamauchi et al., 2009).  
Apart from the plasma membrane, the cytosol and the nucleus, Arl4d can also be found 
in the mitochondria. In fact, studies revealed that myristoylated GTP-defective 
ARL4D(T35N) is tightly associated with the inner membrane of the mitochondria. It not 
only alters the membrane potential but also causes mitochondrial fragmentation, 
indicating that ARL4D(T35N) might play a role in mitochondrial dynamics (Li et al., 
2012). 
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2 Objectives 
 
The adaptive immune system is initiated when CD8 T cell recognize antigen presented 
on the surface of APCs. Recognition of the antigen requires physical contact after which 
the immunological synapse is formed. This specific structure serves as a site of the 
signaling exchange that leads to T cell activation or inhibition. Depending on cell 
phenotype and the outcome of the interaction, different types of IS are observed.  
In the liver, the soluble antigens are cross-presented to CD8 T cells on the surface of 
non-professional APCs, liver sinusoidal endothelial cells. Liver-primed CD8 T cells 
differentiate into nonresponsive cells that possess memory-like function upon infection. 
This unique differentiation state depends on the delivery of co-inhibitory signals from 
PD-L1 on LSECs surface to PD-1 on CD8 T cell surface. However, the further mechanism 
of PD-L1/PD-1 signaling has not been investigated.  
 
The aim of this work was to better characterize the unique interaction between CD8 T 
cells and LSECs that has not been observed in any other organ. Therefore, the following 
questions were addressed: 
 
 What kind of immunological synapse is formed at CD8 T cell-LSEC contact site? 
 
 Does PD-L1 signaling have an impact on immunological synapse formation? 
 
 Is nonresponsive state of liver-primed CD8 T cells reversible by co-stimulation? 
 
 Are there other inhibitory molecules downstream of PD-1 involved in the 
induction of nonresponsiveness? 
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3 Material and Methods 
 
3.1 Material 
3.1.1 Equipment 
Equipment   Name (Company)         
Autoclave   Belimed, Cologne 
AutoMACS   Miltenyi, Bergisch Gladbach 
Camera EMCCD  ImagEM C9100-13 (Hamamatsu Photonics, Japan) 
Cell counting chamber Neubauer (La Fontaine via Labotec, Göttingen) 
Cell culture plates 24-well Corning Cellbind®, flat (Corning Incorporated Life 
Sciences, Lowell/USA); 24-well/48-well/96-well, F- /U-base 
(TPP, Trasadingen/CH) 
Cell sorter   FACSAriaIIITM (Becton Dickinson, Heidelberg) 
Centrifuges Multifuge 3s-r, Biofuge fresco, Biofuge Pico (Heraeus, 
Hanau) 
Cover slips   Round (Marienfeld, Lauda-Königshofen) 
ELISA reader   Mithras LB940 (Berthold Technologies, Bad Wildbad) 
ELISA washer  (Nalge Nunc International, via neoLab, Heidelberg) 
Flow cytometer  Canto II, LSRFortessaTM (Becton Dickinson, Heidelberg) 
Fridge (+4°C) Economic cooler (Bosch, Stuttgart); Liebherr premium, 
Liebherr  comfort (Liebherr, Biberach) 
Freezer (-20°C) Liebherr comfort (Liebherr, Biberach) 
Freezer (-80°C) Hera freeze (Heraeus, Hanau) 
Incubators   Hera cell, Hera cell 240 (Heraeus, Hanau) 
Illumination system  MT20E (Olympus, Japan) 
Light Cycler   LightCycler® 480 II (Roche, Penzberg) 
Microscope   FluoView 1000 and IX81 (Olympus, Japan) 
Pipettes 0.5-10μl, 2-20μl, 20-200μl, 100-1000μl (Eppendorf, 
Hamburg) 
Perfusion pump Masterflex (Cole-Parmer Instrument Company via 
Novodirect, Kehl/Rhein) 
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Petri-dishes 10 cm (Greiner bio-one, Solingen) 
Preperation instruments Labotec, Göttingen 
Shaking water bath  GFL® 1092 (GFL®, Burgwedel) 
Sieves, steel   University of Bonn, Department „Feinmechanik“ 
Slides    26x76mm (Marienfeld via Labomedic, Bonn) 
Workbench, sterile   Hera safe (Heraeus, Hanau) 
 
3.1.2 Chemical and Reagents 
Chemical/Reagent     Company     
Agarose, electrophoresis grade    Invitrogen, Karlsruhe 
Avidin/Biotin Blocking Kit     Invitrogen, Karlsruhe 
Bovine serum albumin (BSA)    Roth, Karlsruhe 
Brefeldin A      eBioscience, USA 
CollagenR solution     Serva, Heidelberg 
Electrophoresis System     Mini-Protean®, Bio-Rad, Munich 
DABCO     Sigma-Aldrich, Steinheim 
DMEM Medium     Gibco BRL, Karlsruhe 
Dimethylsulfoxid (DMSO) ((CH3)2OS)   Merck, Darmstadt 
Donkey serum     Jackson Immunoresearch, USA 
EDTA (C10H12N2O8)     Roth, Karlsruhe 
Ethanol, absolut (C2H4O2)     Applichem, Darmstadt 
Fetal bovine serum (FCS)     PAA, Pasching, Austria 
GBSS     PAA, Pasching, Austria 
Ionomycin     Sigma-Aldrich, Steinheim 
L-Glutamine (200 mM) (C5H10N2O3)   Cambrex, Verviers, Belgium 
beta-mercaptoethanol (HS(CH2)2OH)   Sigma, Deisenhofen 
Monensin     eBioscience, USA 
Nycodenz     Axis-Shield, Norway 
Ovalbumin (OVA)     Serva, Heidelberg 
Pancoll     PAN Biotech, Aidenbach 
Paraformaldehyde (PFA, H(-OCH2)n-OH)    Fluca, Buchs 
PBS     Biochrom, Berlin 
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Penicillin (10,000 U/ml)/Streptomycin (10 mg/ml) PAA, Pasching, Austria 
Percoll     GE Healthcare 
Phorbol-12-myristat-13-acetat (PMA)   Sigma-Aldrich, Steinheim 
ProlongGold     Invitrogen, Karlsruhe 
RPMI 1640 Medium     Gibco BRL, Karlsruhe 
SDS     Applichem, Darmstadt 
Semi-dry Blotter     TE77, Amersham via  
GE Healthcare, Freiburg 
Sodium azide (NaN3)     Sigma, Deisenhofen 
Sodium hydroxide (NaOH)     Merck, Darmstadt 
TMB-Substrate     Pierce, Bonn 
Tris (C4H11NO3)     Roth, Karlsruhe 
Tris-Buffered Saline (TBS)     Applichem, Darmstadt 
Triton X-100                Promega, USA 
Trypan Blue     Serva, Heidelberg 
Tween-20     Merck, Darmstadt 
 
3.1.3 Antibodies 
3.1.3.1 Flow cytometry 
Antigen Isotype Clone Company 
CD4 Rat IgG2a κ RM4-5 eBioscience 
CD8α Rat IgG2a κ 53.6-7 BioLegend 
CD25 Rat IgG1 κ PC61.5 eBioscience 
CD44 Rat IgG2b  IM7 eBioscience 
CD45.1 Rat IgG2a κ A20 eBioscience 
CD45.2 Rat IgG2a κ 104 eBioscience 
CD62L Rat IgG2a κ MEL-14 eBioscience 
CD90.1 (Thy1.1) Rat IgG2a κ HIS51 eBioscience 
CD127 Rat IgG2a κ A7R34 eBioscience 
CD279 (PD-1) Hamster IgG J43 eBioscience 
IL-2 Rat IgG2a κ JES6-5H4 eBioscience 
IFNγ Rat IgG1 κ XMG1.2 eBioscience 
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Isotype control Rat IgG1 κ eBRG1 eBioscience 
Isotype control Rat IgG2a κ eBRG2 eBioscience 
KLRG1 Hamster IgG 2F1/KLRG1 BioLegend 
 
Antibodies were directly fluorochrome labeled. Depending on fluorochrome-conjugate, 
antibodies were used in following dilutions: 
- FITC, Alexa488 1:100 
- PE, APC, PercpCy5.5, PE-Cy7, eFluor 450, BV421, Pacific Blue, BV650 1:200/1:300 
 
3.1.3.2 ELISA 
Antigen Isotype Clone Conjugate Company 
IFNγ Rat IgG1 R46A2 Purified eBioscience 
IFNγ Rat IgG1 XMG1.2 Biotin eBioscience 
IL-2 Rat IgG2a JES6-1A12 Purified eBioscience 
IL-2 Rat IgG2b JES6-5H4 Biotin eBioscience 
 
3.1.3.3 Functional antibodies 
Antigen Isotype Clone Company 
CD28 Golden Syrian 
Hamster IgG 
37.51 eBioscience 
Isotype control Golden Syrian 
Hamster IgG 
 eBioscience 
CD3  145-2C11 Institute of Molecular Medicine, Bonn 
CD28  PV-1 Institute of Molecular Medicine, Bonn 
 
3.1.3.4 Immunofluorescence 
Primary antibodies 
Target  Host Clone Conjugate Company 
TCRβ Armenian  
Hamster IgG 
H57-597 Biotin eBioscience 
CD11a Rat IgG2a I21/7 Purified Southern Biotec 
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Secondary antibodies 
Target Host Clone Conjugate Company 
Rat Goat  H+L Cyanine3 (Cy3) Jackson 
Immunoreserach 
Biotin  Streptavidin  Cyanine5 (Cy5) Jackson 
Immunoreserach 
Armenian  
Hamster  
Goat H+L AlexaFluor488 Molecular Probes 
Rat Goat H+L AlexaFluor488 Molecular Probes 
 
3.1.3.5 Western Blot antibodies 
Primary antibodies 
Antigen Conjugate Company 
β-actin Purified Santa Cruz Biotechnology 
CD3ζ Purified Proteintech Europe 
pCD3ζ Purified BD Bioscience 
Lck Purified Cell Signalling Technologies 
pLck Purified Cell Signalling Technologies 
 
Secondary antibodies 
Antigen Conjugate Company 
Rabbit HRP Santa Cruz Biotechnology 
Goat HRP Santa Cruz Biotechnology 
 
3.1.4 Beads 
Antibody-coated beads   Company 
Anti-CD8 (MACS)   Miltenyi, Bergisch Gladbach 
Anti-CD146 (MACS)   Miltenyi, Bergisch Gladbach 
Anti-CD11c (MACS)   Miltenyi, Bergisch Gladbach 
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Fluorochrome-coated beads  Company 
CountBrightTM absolute counting beads Invitrogen, Karlsruhe 
 
3.1.5 Kits 
All kits were used according to manufacturers instructions provided by the manual. 
 
Name     Company 
CD8α Isolation Kit      Miltenyi, Bergisch Gladbach 
LIVE/DEAD Fixable NearIR Dead Cell Stain Kit  Invitrogen, Karlsruhe 
RNeasy® Mini Kit     Qiagen, Hilden  
SuperScript®VILOTM     Invitrogen, Karlsruhe 
 
3.1.6 Enzymes 
 
Name  Company 
Collagenase    Sigma, Steinheim and Roche, Basel 
Peroxidase  Pierce, Bonn 
 
3.1.7 Cell culture media 
 
LSEC medium    DMEM high Glucose (4500 mg/l)  
10% (v/v) FCS  
105 U Penicillin 
       0.1 g/l Streptomycin  
2 mM L-Glutamine 
 
T cell medium    RPMI 1640  
   8% (v/v) FCS  
105 U Penicillin 
0.1 g/l Streptomycin 
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2 mM L-Glutamine  
50μM β-mercaptoethanol 
 
3.1.8 Buffers 
 
ACK Lysis Buffer     16.58 g NH4Cl  
2 g KHCO3  
74.4 mg EDTA  
2000 ml H2O  
pH 7.2-7.4 
 
EDTA (0,5 M)     186.1 g EDTA  
approx. 20 g NaOH  
1000 ml H2O  
pH 7.8-8.0 
 
 
ELISA Blocking Buffer   0.5% (w/v) BSA in PBS 
 
ELISA Coating Buffer   0.1 M NaHCO3, pH 8.2 
 
ELISA Washing Buffer   0.05% (v/v) Tween-20 in PBS 
 
FACS Buffer     PBS  
1% (v/v) FCS  
2 mM EDTA 
0,02% (w/v) NaN3 
 
GBSS  (Gey’s balanced salt solution) 5 mM KCl  
1,6 mM CaCl2  
0,9 mM MgCl2  
0,3 mM MgSO4  
0,2 mM KH2PO4  
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1,7 mM Na2HPO4 (pH 7,4)  
2,7 mM NaHCO3  
5,5 mM D(+)-Glukose  
50 mM HEPES  
pH 7,4 
 
 
Liver Perfusion Buffer   0.01 g L- Aspartic acid 
0.02 g L-Threonine 
0.03 g L-Serine 
0.04 g Glycine 
0.05 g L-Alanine 
0.13 g L-Glutamic acid 
0.13 g L-Glutamine 
3.6 g D(+)-Glucose 
3.6 g D(-)-Fruktose 
67.4 g Sucrose 
0.22 g KCl 
0.1 g NaH2PO4* H2O 
0.1 g MgCl2* 6 H2O  
2.4 g HEPES  
2.0 g NaHCO3 
1000 ml H2O 
0.05% (v/v) Collagenase 
 
MACS Buffer     PBS  
1% (v/v) FCS  
2 mM EDTA 
pH 7,2 
 
PBS      80 g/l NaCl  
(phosphate buffered saline)  0.2 g/l KCl 
1.44 g/l NaHPO4*2 H2O 
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0.2 g/l KH2PO4 
pH 7.4 
 
Spleen Perfusion Buffer   GBSS 
      0.5% (v/v) Collagenase 
 
TBS (10x)     200mM Tris 
(tris buffered saline)   1.26M NaCl 
      pH 7.6 
 
TBS/T      TBS 
      0.1% (v/v) Tween 20 
 
Western Blot: Lysis Buffer   20 mM Tris-HCl (pH 7,5) 
      150 mM NaCl 
      1 mM EGTA 
      1 mM EDTA 
      2.5 mM sodium pyrophosphate 
      1 mM β-glycerophosphate 
      1 mM sodium vanadate 
      1% (v/v) Triton X-100 
 
Western Blot: Loading Buffer  0,58 M Sucrose  
4% (w/v) SDS  
0,04% (v/v) Bromphenol blue  
62,5 mM Tris/HCl  
60 mg/ml DTT  
pH 6,8 
 
Western Blot: SDS-Running buffer  3 g Tris/HCl  
14,4 g Glycin  
1 g SDS  
1000 ml H2O 
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3.1.9 Animals 
Experimental animals were kept under SPF (specific pathogen free) conditions in The 
House of Experimental Therapy (HET) or Institute of Molecular Medicine and 
Experimental Immunology (IMMEI) at the University Hospital Bonn. 
 
Mouse strain   Description 
Arl4dtm1a(EUCOMM)Wtsi   Knockout of Arl4d molecule 
PD-L1-/-    Knockout of PD-L1 (B7H1) molecule 
PD-1-/-    Knockout of PD-1 molecule 
C56BL/6     Inbred strain expressing the MHC I haplotype H-2b 
(wild type mouse) 
OT-I Mouse strain bearing transgenic TCR on CD8 T cells, 
recognizing OVA257-264 peptide on H2-Kb molecules 
Arl4d OT-I Crossed Arl4dtm1a(EUCOMM)Wtsi with OT-I mouse strain 
 CD8 T cells of these mice are Arl4d-deficient and 
specific recognize OVA257-264 peptide on H2-Kb 
molecules 
CD45.1 OT-I Crossed CD45.1 with OT-I mouse strain. Cells of these 
mice express CD45.1 that is used as a congenic 
marker to distinguish them from wild type (CD45.2) 
cells 
Arl4d CD45.1 OT-I Crossed Arl4dtm1a(EUCOMM)Wtsi with CD45.1 OT-I mouse 
strain 
CD90.1 Cells of these mice express CD90.1 that is used as a 
congenic marker to distinguish them from wild type 
(CD90.2) cells 
3.1.10 Recombinant viruses 
Name Description 
Ad-GOL Recombinant adenovirus expressing GFP, Ovalbumin 
and Luciferase driven by CMV promoter. Provided by 
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Dr. Dirk Wohlleber (Institute of Molecular 
Immunology, Munich) 
 
3.1.11 Primers 
Name  Company 
Arl4d TaqMan® Expression Assay  Life Technologies, Darmstadt 
(#Mm01249825_m1) 
 
IL-2 TaqMan® Expression Assay  Life Technologies, Darmstadt 
(#Mm00434256_m1) 
 
3.1.12 Software 
Name Application   Company 
Cell-R Microscopy data  Olympus 
Excel 2011 Data analysis   Microsoft 
FACS Diva V8.0.1 FACS measurement  BD Bioscience 
FlowJo Version 9 FACS data analysis  Tree Star 
Illustrator CS3 Graphic design  Adobe 
ImageJ Microscopy image  NIH, USA 
 analysis 
Microwin 2000 V4.37 ELISA analysis  Mikrotek Laborsystem 
 
 
Prism5 Statistics and graphic Graph Pad Software 
 design 
Word 2011 Documentation  Microsoft 
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3.2 Methods 
3.2.1 Isolation of primary cells 
All experimental animals were sacrificed by cervical translocation. Afterwards the body 
surface was cleaned with 70% ethanol and the body cavity was opened under semi-
sterile conditions using surgical instruments. 
3.2.1.1 LSEC isolation 
In order to isolate liver sinusoidal endothelial cells (LSECs), the digestion of the liver 
tissue is required and was performed as follows. The portal vein (Vena porta) was first 
cannulated followed by the perfusion of the liver with perfusion buffer at the speed of 4 
ml/min for 10-20 seconds. Blood was pumed out via Vena cava that had been opened at 
the start of perfusion. The liver was perfused until it turned yellow and transferred into 
the GBSS buffer, gallbladder was cut carefully. Afterwards collected livers were 
transferred into petri dish and all fluids were removed. The organs were minced using 
scissors, transferred into 50 ml tube and resuspend in 3ml GBSS containing 0,05% 
Collagenase per liver. The cell suspension was incubated for 15 min in 370C while 
shaking (240rpm). After incubation, digested tissue was passed through a 250μm steel 
sieve, washed with GBSS and centrifuged (1500 rpm, 10 min, 200C). The organ mass was 
resuspended in 1 ml fresh GBSS and transferred into 15 ml tube. Next, 1.23 fold 30% 
(v/v) warm (370C) Nycodenz was added. The cell suspension was mixed thoroughly and 
overlaid with 500-1000μl GBSS in order to prevent LSECs from drying out after 
centrifugation. The gradient centrifugation was performed for 20 min at the speed of 
1400xg without brakes. The white-ring cell layer was collected in 1 ml MACS buffer, 
transferred into 50 ml tube and washed with MACS buffer (1500 rpm, 10 min). The 
purification of LSEC was performed using magnetic cell separation (MACS). Afterwards 
the cells were resuspended in LSEC medium at the concentration of 1*106/ml and 
cultured in Corning Cellbind® 24-well or 96-well plates (0,5*106 and 0,2*106 cells per 
well, respectively). For microscopy imaging non-coated 24-well plates were used. Each 
well contained glass cover slip, which had been coated with collagen (CollagenR 
solution, 1:10 dilution in distilled water) prior to LSEC isolation. One day after seeding, 
LSECs were washed with warm PBS containing 2% FCS in order to get rid of dead cells 
and debris. On day 2 or 3 after isolation, LSECs were used for further experiments. 
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3.2.1.2 Isolation of liver-associated lymphocytes 
In order to isolate lymphocytes from the liver, organs were collected in GBSS and passed 
through 250μm steel sieve. Cells were washed with GBSS (1500 rpm, 10 min), 
resuspended in 10ml 40% Percoll solution (40% Percoll in PBS, v/v) and underlaid with 
2 ml Pancoll solution. The gradient centrifugation was performed at the speed of 800xg 
for 20 min without brakes. Afterwards the upper layer containing hepatocytes and dead 
cells was discarded and the interface containing lymphocytes was collected for the in 
vitro stimulation. 
 
3.2.1.3 Isolation of splenic CD8 T cells 
In order to isolate CD8 T cells, spleens were collected in T cell medium and passed 
through 250μm steel sieve. Cells were washed ones (1500 rpm, 10 min), taken up in 
warm T cell medium and transferred into separation columns (syringes filled with 0.6g 
nylon wool per 10ml). After 45 min incubation time at 370C, columns were washed with 
T cell medium (2x syringe volume) and flow through containing lymphocytes was 
collected into 50 ml tube (other cells like macrophages and DCs adhered to the nylon 
wool). Cells were washed ones with T cell medium and onces with MACS buffer (1500 
rpm, 10 min). CD8 T cells were purified using magnetic cell separation (MACS) and used 
for further experiments. When OT-I CD8 T cells were isolated, OT-I mice were injected 
(i.p.) 2 days before isolation with 300μg anti-NK1.1 antibodies in order to deplete NKT 
cells. 
 
3.2.1.4 Isolation of splenic DCs 
In order to isolate DCs, spleens were collected in PBS. Afterwards organs were 
transferred into petri dish and injected with warm spleen perfusion buffer and 
incubated for 20 min at 370C. Next, spleen were passed through steel sieves and washed 
with MACS buffer (1500 rpm, 10 min). CD11c+ DCs were purified using magnetic cell 
separation (MACS) and used for further experiments. 
 
3.2.1.5 Isolation of cells from the blood 
In order to isolate cells from the blood, 32μl of blood were taken from the tail vein and 
transferred into PBS. After centrifugation (3000rpm, 5 min), cell pellets were 
Material and Methods 
 
39 
 
resuspended in ACK lysis buffer and incubated for 10 min at RT. Subsequently, cells 
were centrifuged (3000rpm, 5 min) and cell pellets were resuspended in FACS buffer 
and stained for FACS analysis. 
 
3.2.1.6 Isolation of splenocytes 
In order to isolate splenocytes, spleens were collected in PBS and passed through 
250μm steel sieve. Cell suspension was washed in PBS (1500 rpm, 10 min), resuspended 
in FACS buffer and stained for FACS analysis. 
 
3.2.2 Magnetic cell separation (MACS) 
In order to purify the desired cell population from the whole organ, MACS seperation 
was performed. Cell suspension was incubated for 15 min in 40C with desired antibody-
coated beads (3.1.4 or 3.1.5) in MACS buffer (positive selection) or in two steps 
(negative selection): first step for 10 min and second step for 15min, both in 40C. 
Afterwards, cells were washed (1200 rpm, 10 min) in MACS buffer to remove the 
unbound beads. Cell suspension was resuspend in 3ml MACS buffer and passed through 
nylon sieve. Depending on the used beads either positive or negative selection (program 
POSSEL or DEPLETE) was performed on AutoMACS (Miltenyi). 
In order to obtain specific cell populations, the following protocols were used: 
 
Cell type  Beads     Selection 
 
LSEC   24μl anti-CD146/liver  POSSEL 
CD8 T cells  20μl anti-CD8/spleen  POSSEL 
CD8 T cells  50μl/100*106 cells    DEPLETE 
   biotin-antibody cocktail; 
   100μl/100*106 cells 
   anti-biotin beads 
DC   20μl anti-CD11c/spleen  POSSEL 
3.2.3 Cell culture 
All isolated cells were cultured at the following conditions: 
Material and Methods 
 
40 
 
 temperature – 370C 
 relative humidity – 90% 
 CO2 – 5% 
 
3.2.3.1 Antigen-specific stimulation of CD8 T cells by either LSEC or DC 
2-3 days mature LSECs were used for further experiments, when they were 85-100% 
confluent. 1*106 or 2*105 isolated CD8 T cells were added to each well with LSECs in 
1000μl T cell medium or 200μl (24-well plate and 96-well plate, respectively) and 
cocultred for the indicated time points. DCs were freshly isolated at the same day as CD8 
T cells, mixed 1:2 and cocultured in 1000μl T cell medium (24-well plate) for the 
indicated time points. In all experiments, for antigen-specific stimulation of CD8 T cells, 
OVA was applied at a concentration of 100μg/ml.  
 
3.2.3.2 Stimulation of CD8 T cells with antibodies 
Prior to CD8 T cell isolation, 96-well plate was coated with anti-CD3 (2μg/ml) and anti-
CD28 (10μg/ml) in PBS. After 2 hours of incubation at 370C, plate was washed three 
times with PBS. 2*105 CD8 T cells were cultured in 200μl T cell medium for indicated 
periods of time. 
 
3.2.3.3 Restimulation of CD8 T cells 
CD8 T cells from co-culture or in vivo experiments were restimulated with PMA 
(5ng/ml) and Ionomycin (200ng/ml) in T cell medium for 4 hours at 370C. In addition, 
Brefeldin A and Monensin (1:1000) were added to prevent the secretion of cytokines to 
the medium. Afterwards, CD8 T cells were washed once with T cell medium and once 
with FACS buffer (1500 rpm, 10 min) and stained intracellularlly for FACS analysis. 
 
3.2.3.4 Calculation of the cell number 
The cell number was determined using Neubauer Cell Chamber. 10μl of the cell 
suspension was mixed with 90μl Trypan Blue and transferred into the chamber. Non-
stained cells (live cells) in 4 big squares were counted. The calculation was performed 
using the following formula: 
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𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 (
1
𝑚𝑙
)
=
𝑐𝑜𝑢𝑛𝑡𝑒𝑑 𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟
4
× 10(𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛) × 1000(𝑐ℎ𝑎𝑚𝑏𝑒𝑟 𝑓𝑎𝑐𝑡𝑜𝑟) 
 
3.2.4 Antigen-specific stimulation of CD8 T cells in vivo 
3.2.4.1 Adoptive transfer 
Sorted naive OT-I CD8 T cells from spleens were adoptively transferred by intravenous 
injection (i.v.) at the amount of 8*105 cells/mouse. 
 
3.2.4.2 Infection with the recombinant Adenovirus 
One day after adoptive transfer, mice were infected with non-replicating AdGOL. The 
virus was diluted in NaCl solution and injected i.v. at the amount of 5*106 PFU/mouse. 
 
3.2.4.3 Analysis of CD8 T cell response 
Cells from blood (3-8 days after infection), spleen (8 days after infection) and liver (8 
days after infection) were isolated as described in 3.2.1.5, 3.2.1.6 and 3.2.1.2, 
respectively. In order to track adoptively transferred cells, cells were stained for the 
indicated congenic markers (CD45.1, CD45.2 or CD90.1) and measured by FACS. 
Additionally, cells were stained with antibodies against CD8, CD44, CD62L, KLRG1 and 
CD127 in order to determine development of effector cells after infection. 
Eight days after infection splenocytes and liver-associated lymphocytes were 
restimulated as described in 3.2.3.3 and stained intracellulary for IL-2 and IFNγ. 
 
3.2.5 Flow cytometry 
3.2.5.1 Staining of the surface markers 
In order to stain markers expressed on the cell surface, 105-5*106 cells were stained in 
in 96-well plate or FACS tubes containing 50μl and 500μl FACS buffer with specific 
antibodies, respectively. Cells were incubated for 15 min at 40C. Afterwards cells were 
washed two times in FACS buffer (2 min, 1600rpm), resuspended in 100-200μl FACS 
buffer and measured on FACS Canto II or LSRFortessaTM (BD Bioscience). 
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3.2.5.2 Intracellular staining of cytokine production 
After restimulation, as described in 3.2.3.3, cells were washed in FACS buffer (2 min, 
1600rpm) and stained for surface molecules (3.2.5.1). Next, cells were washed once (2 
min, 1600rpm) and fixed in 100μl PFA (4% w/v in PBS) for 10 min at RT. After washing 
once with FACS buffer and once with 1x PERM Buffer (eBioscience, 2 min, 1600rpm), 
intracellular staining was performed in 96-well plates in PERM Buffer containing 
specific antibodies for 30 min on ice. After incubation time, cells were washed once with 
PERM Buffer, once with FACS buffer and resuspended in FACS buffer. For every staining 
an isotype control staining was applied. 
 
3.2.5.3 Live/Dead staining 
In order to distinguish between live and dead cells, specific Live/Dead staining is 
required. Depending on the experiment two different fluorophores were used: 
 Hoechst 33258: added prior to measurement at final concentration 10μg/ml 
 LIVE/DEAD Fixable NearIR Dead Cell Stain Kit: added during staining with 
surface markers at the concentration of 1:1000 
All cells positive for the indicated fluorophores were considered as dead cells and were 
excluded from the analysis. 
 
3.2.5.4 FACS sorting for adoptive transfer 
Spleens were collected and mashed through metal sieve. Next, CD8 T cells were isolated 
from whole splenocytes using the „CD8α T cell isolation Kit“. In order to sort pure naive 
CD8 T cell population, cells were stained in 500μl MACS buffer for CD8, CD44 and CD62L 
for 15 min at 40C. CD8 T cells were sorted at 40C into 15 ml tubes filled with 2ml T cell 
medium. 
 
3.2.5.5 Cell number determination by FACS 
In order to determine cell number, 5000 CountBrightTM absolute counting beads were 
added to each sample prior to acquisition on FACS CantoI or LSRFortessaTM (BD 
Bioscience). The calculation was performed using the following formula: 
 
𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟(𝑠𝑎𝑚𝑝𝑙𝑒) =
𝑐𝑜𝑢𝑛𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
𝑐𝑜𝑢𝑛𝑡𝑒𝑑 𝑏𝑒𝑎𝑑𝑠
𝑥5000(𝑎𝑑𝑑𝑒𝑑 𝑏𝑒𝑎𝑑𝑠) 
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To calculate cell number in the organ, total cell number was multiplicated with the 
respective dilution factor. 
 
3.2.6 ELISA  
In order to determine the cytokine concentration in supernatants, the sandwich enzyme 
linked immunosorbent assay (ELISA) was performed as follows. 96-well plate were 
coated either 1 hour in 370C or overnight in 40C with 50μl/well ELISA-Coating Buffer 
containing primary antibodies (1:500). Next, plates were washed three times with 
ELISA-Washing buffer and blocked with 100μl/well ELISA-Blocking buffer for 30 min at 
RT. After three subsequent washing steps, 50μl/well cell culture supernatant was added 
to each well and incubated for 1 hour at 370C. Additionally, blank controls (medium 
alone) and standard controls (titreted 1:4) were included. Plates were incubated for 1 
hour at 370C or overnight at 40C. After three times of washing, secondary biotin-coupled 
antibodies were added (1:500) and plates were incubated for 1 hour in 370C). Next, 
plate was washed three times and incubated with 50μl/well streptavidin conjugated 
horseradish peroxidase (POX, 1:1000 in PBS) for 30 min at 40C. After three times of 
washing, 80μl/well TMB was added. A few minutes later, optical density (OD) was 
measured using an ELISA reader. 
 
3.2.7 Microscopy 
3.2.7.1 Immunofluorescence staining  
Cells were cultured on coverslips (see 3.2.1.1). At the indicated time periods, coverslips 
were fixed with 4% PFA (w/v in PBS) on ice for 10 min. Next, washed three times with 
1xTBS and blocked with 1% BSA + 5% donkey serum (Jackson Immunoresearch) for 30 
min at RT. After three times of washing with 1xTBS, cells were stained with primary 
antibodies in 1% BSA and incubated for 1 hour at RT in the dark. Next, coverslips were 
washed three times with 1xTBS and stained with secondary antibodies in 1% BSA for 30 
min at RT in the dark. Then, coverslips were washed two times with 1xTBS and one time 
with distilled water. After washing, coverslips were mounted in a one drop of Prolong 
Gold (Invitrogen) + anti-fade reagent DAPCO (Sigma-Aldrich). 
Antibodies used for staining are listed in 3.1.3.4. The following dilutions were used: 
Material and Methods 
 
44 
 
 rat anti-CD11a 1:100 
 biotin TCRβ 1:50 
 anti-rat Alexa 488 1:200 
 streptavidin Alexa488 1:200 
 anti-rat cy5 1:200 
 streptavidin cy3 1:200 
 
During staining for TCRβ an additional step (between first washing with 1xTBS and 
blocking with 1% BSA + 5% donkey serum) was included: coverslips were incubated 
with Biotin Block solution A (Invitrogen) for 15 min, washed one time with 1xTBS and 
incubated with Biotin Block solution B (Invitrogen) for 15 min. After three times of 
washing with 1xTBS staining was continued as described above.  
 
3.2.7.2 TIRF and confocal microscopy 
In order to investigate the immunological synapse formed at the CD8 T cell-LSEC 
interface, total internal reflection fluorescence (TIRF) microscopy and confocal 
microscopy were used. 
TIRF and epifluorescence microscopy was performed using an Olympus XI81 equipped 
with 60x 1.49 NA Apochromat objective and an EMCCD camera (16 x 16 µm2 pixel size; 
ImagEM C9100-13, Hamamatsu Photonics). In addition, 2x and 1.6x supplementary 
magnifying lens were also used during imaging resulted images with 83.3 nm pixel size.  
For illumination, the device is coupled with both an illumination system MT20E and a 
488 nm laser (LAS/488/20, Olympus) for epifluorescence and TIRF microscopy modus, 
respectively. The system was operated using the Olympus CellR software (Olympus, 
Japan). 
Confocal microscopy was performed using an Olympus FluorViewTM FV1000 microscope 
equipped with an UPlanSApo 60x NA 1.35 objective (Olympus, Japan). For confocal 
illumination 543 nm laser line (cy3) and 633 nm laser line (cy5) were used. Recording 
was performed using Fluoview 3.0 software (Olympus, Japan). 
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3.2.7.3 Autocorrelation analysis 
In order to calculate cluster size autocorrelation analysis was performed using the 
ImageJ program. Squared regions of interest (ROI) with a size of 45 pixels x 45 pixels 
were placed on the contact size. Then the selected ROI was duplicated to generate the 
reference ROI and correlated with the original image yielding a correlation coefficient of 
1. Afterwards, the ROI was displaced pixel-wise up to 7 pixels and duplicated 
simultaneously on each shifted position and correlated with the reference ROI to 
calculate the correlation coefficient after each displacement. The operation was 
performed in all four directions (up, down, right, left) and the four values were 
averaged. The calculated values were plotted against the number of pixel shift yielding 
an autocorrelation decay curve for the respective ROI. Autocorrelation curves from 
individual cells were averaged for one independent experiment.  
 
3.2.8 Gene expression array 
Gene expression array has been performed in cooperation with Institute of Pathology, 
University Hospital in Bonn, by Dr. Lukas C. Heukamp and was performed as described 
(Biermann et al., 2007) . In short, for the analysis 1*106 CD8 T cells from co-culture with 
LSECs were used. We performed RNA isolation using „RNeasy Mini Kit“ (Qiagen) 
according to manufacturer’s recommedations and the further analysis was perfomed in 
Institute of Pathology. The RNA quality was assessed by Agilent Bioanalyzer 2000 
(Agilent Technologies, Palo Alto, CA, USA) and only sample with RIN (RNA integrity 
number) values > 8 were used for the analysis. Probe preparation, hybridization, image 
generation and analysis were performed according to the manufacturer’s guidelines for 
the AB1700 Microarray system. Autogridding, basic quality control, feature extraction, 
background correction, spot and spatial normalization were carried out with the 
Applied Biosystems 1700 Chemiluminescent Microarray Analyzer according to the 
manufacturer’s instructions. The bioinformatic data were normalized by quantile 
normalization and transformed to log2 scale, using Bioconducter 
(http://www.bioconductor.org/docs/faq/)R software and the AB1700 Data Analysis 
script (Yongming, Andrew Sun, Applied Biosystems).  
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3.2.9 Western Blot 
Cells from coculture were collected and lysed in WB Lysis Buffer. Afterwards cell lysetes 
were taken up in WB Loading buffer and incubated 5 min in 950C. The protein 
concentration was measured by BioRad DC assay. Next, electrophoresis chamber was 
filled with SDS-loading buffer. The equal amounts of the protein were transferred on 
SDS-poliacrylamide gel. Further, the gel was blotted on PVDF membrane. The protein 
was detected using proper primary antibodies diluted in TBS/T with 5% (w/v) BSA and 
incubated overnight in 40C. Afterwards, the membrane was washed and HRP conjugated 
secondary antibodies were added and incubated for 1 hour. HRP was detected via „ELC 
plus Western blot detection system“ accroding to the manufacturer’s guidelines. 
 
3.2.10 Real-time PCR 
RNA isolation was performed using the „RNeasy Mini Kit“ (Qiagen) according to 
manufacturer’s recommedations. 1μg RNA was transcribed using the 
SuperScript®VILOTM kit (Invitrogen) into cDNA. To analyse Arl4d and IL-2 expression 
Arl4d TaqMan® Expression Assay (#Mm01249825_m1) and IL-2 TaqMan® Expression 
Assay (#Mm00434256_m1) were used. Real-time PCR was performed using the 
LightCycler®480 II (Roche Diagnostics) for 40 cycles (950C for 15s and 600C for 1 min). 
GAPDH was used as reference gene. 
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4 Results 
 
4.1 The immunological synapse formed by CD8 T cells and LSEC is not affected 
by PD-L1/PD-1 interaction 
4.1.1 Contact of CD8 T cell with LSEC results in multifocal immunological 
synapse formation 
Antigen recognition by T cells and their activation initiate adaptive immune 
responses.  
Direct contact of T cell and APC results in immunological synapse (IS) formation, 
which consists of TCR-pMHC clusters (cSMAC), surrounded by adhesion molecules 
(pSMAC) (Alarcon, 2011; Thauland and Parker, 2010; Monks, 1998). So far several 
types of IS have been described: a classical bull’s eye synapse, a multifocal synapse 
and a kinapse (Dustin, 2009; Alarcon, 2011). To investigate what kind of IS 
characterizes the LSEC-CD8 T cell interaction, we co-cultured naїve H2Kb-OVA 
specific CD8 T cells with OVA-loaded LSEC on collagen-coated coverslips for 30 and 
60 minutes, to visualize early time points of IS formation (Fig 6A). Afterwards the 
cells were fixed and stained for TCRβ (green), which is associated with the cSMAC, 
and the LFA-1 subunit CD11a (red), which is associated with the pSMAC. Then the T 
cell-APC contact site was visualized using confocal microscopy. We found that 
antigen-specific interaction of CD8 T cells with LSECs results in TCRβ and CD11a 
cluster formation. TCRβ and CD11a clusters did not overlap and were spread all 
over the contact area, indicating that multifocal immune synapse was formed 
(Hailman et al., 2002; Brossard et al., 2005). As the CD8 T cells upon antigen 
recognition presented by LSECs stop migrating (von Oppen et al., 2009), we did not 
observe a kinapse.  
 
4.1.2 PD-L1/PD-1 signaling rapidly interferes with TCR signal transduction 
We have previously discovered that CD8 T cells primed in the liver under 
noninflammatory conditions by antigen presenting LSEC develop 
nonresponsiveness. Thus, they are not able to perform immediate cytotoxic 
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functions or to produce cytokines (Diehl et al., 2008; Böttcher et al., 2013) upon 
restimuation. Furthermore, interaction of CD8 T cells with antigen-presenting LSECs 
induces PD-L1 expression on these APCs and the unique CD8 T cell state is PD-L1-
dependent (Diehl et al., 2008, Schurich et al., 2010).  
It is reported that PD-1 expression is induced on activated T cells, B cells and NKT 
cells (Sharpe et al. 2007, Agata et al. 1996). As PD-1 expression on LSEC-primed CD8 
T cells has not been investigated, we co-cultured wild type CD8 OT-I T cells with 
LSEC and we analyzed PD-1 expression for indicated times by flow cytometry (Fig 
6B). 
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Figure 6. Naive CD8 T cell-LSEC interaction resembles a multifocal synapse. 
A: OVA-loaded B6 were cultured with naïve OT-1 CD8 T cells and after the indicated times cells were 
fixed and stained for TCR (green) and the LFA-1 subunit CD11a (red) and analyzed by confocal 
microscopy. Line-scans show signal intensities (arbitrary units) along the dotted lines for TCR 
(green) and CD11a (red) in the overlay. Scale bar shows 10 m. Representative data from 3 
independent experiments are shown. Images are shown at arbitrary scaling. B: Naïve OT-1 T cells 
were co-cultured with B6 LSEC with or without OVA for the indicated times and stained for CD8 and 
PD-1. The histogram shows PD-1 expression over time gated on viable CD8 T cells. Filled grey 
histogram represents isotype control staining. Bar graph shows mean fluorescence intensity (MFI) of 
PD-1. D: OT-1 CD8 T cells were cultured with antigen-presenting wild type or PD-L1 (B7H1)-/- LSEC 
for the indicated times after which cell lysates were probed for protein expression by western blot as 
indicated and quantified. E: Wild type or PD-1-/- OT-1 CD8 T cells were cultured with antigen-
presenting LSEC for the indicated times after which IL-2 mRNA levels were determined by real time 
PCR. Representative data from at least 3 independent experiments are shown. Data are shown as 
mean +/- SEM. Significance was calculated by ANOVA. *p0.05, **p0.01, ***p0.001. 
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PD-1 expression was antigen-dependently induced within 1-4 hours of T cell-APC 
interaction reaching a maximum at 24 hours (Fig 6B), indicating co-inhibitory 
signaling to T cells via PD-L1 on LSECs could occur early and was retained for at 
least 5 days (Fig. 6C). 
It was shown that PD-1 down-modulates TCR signaling by inhibiting the TCR-
associated phosphorylation of CD3ζ and ZAP70 (Sheppard et al., 2004; Dai et al., 
2014). As we observed continuous expression of PD-1 on LSEC-stimulated CD8 T 
cells we wondered whether TCR proximal signaling is inhibited. For this reason, we 
co-cultured naïve CD8 T cells with either B6 or B7H1-/- (PD-L1-deficient) LSECs and 
performed western blot analysis. As shown in Fig. 6D, TCR signaling was detected 
within the first 10 minutes by phosphorylation of the CD3ζ chain. Furthermore, 
CD3ζ chain phosphorylation was attenuated over time in B6 LSEC-primed CD8 T 
cells. Interestingly, phosphorylation of CD3ζ and Lck, which is required for CD3ζ 
phosphorylation, was enhanced in the absence of PD-L1/PD-1 signaling as soon as 
30’ to 60’, indicating that early attenuation of TCR proximal signaling in LSEC-
stimulated CD8 T cells is PD-L1/PD-1-dependent.  
PD-1 signaling has been shown to inhibit IL-2 production in T cells (Carter et al., 
2002). We found that within 60’ of LSEC stimulation IL-2 mRNA induction in naïve 
PD-1-/- CD8 T cells was significantly increased as compared to the wild type CD8 T 
cells, indicating that PD-1 signals are rapidly translated into differential response as 
early as 30’-60’ after antigen-dependent stimulation by LSECs (Fig 6E). 
Changes in TCR signal strength can lead to changes in immune synapse cluster 
formation: weaker proximal TCR signaling correlated with smaller TCR clusters 
(Yokosuka et al., 2005). Hence, we further studied whether the observed increase in 
TCR signaling strength in the absence of PD-L1-dependent signals influences IS 
formation. Thus, we cocultured naïve OT-I CD8 T cells with OVA-loaded PD-L1-
deficient LSEC for the indicated times and stained for TCRβ and CD11a as depicted 
in Fig. 6A. As shown in Fig. 7, confocal microscopy revealed that also here a 
multifocal IS was formed. Taken together, formation of a multifocal synapse upon 
direct antigen-specific contact of CD8 T cell with LSEC is not influenced by PD-L1 
signals. 
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Figure 7. The absence of PD-L1 signaling did not prevent multifocal synapse 
formation. 
OVA-loaded PD-L1 (B7H1)-/- LSECs were cultured and stained as in Fig. 6A and analyzed by confocal 
microscopy. Scale bar shows 10 m. Images are shown at arbitrary scaling. 
 
4.1.3 LSEC-mediated PD-L1 signals do not affect TCRβ and CD11a cluster 
formation 
Although we found that PD-L1 signaling did not influence the spatial distribution of 
TCR and CD11a clusters within the interface between LSECs and T cells, we were 
interested whether the size and density of the individual TCR and CD11a clusters 
in the membrane were altered due to the lack of PD-L1 expression on LSECs. To 
visualize single TCR or CD11a protein clusters in the T cell membrane, we used 
total internal reflection fluorescence (TIRF) microscopy (Fig. 8). Using TIRF, we 
could perform a more detailed quantitative analysis of cluster density and size.  
 
 
 
 
Figure 8. Schematic view of TIRF illumination principle (Mattheyses et al., 2010). 
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The excitation beam enters at the incident angle θ, which is bigger than critical angle θc. While 
excitation beam is reflected off the coverslip, evanescent field is formed on the other side of coverslip, 
where fluorophores are excited (green points). By means of TIRF fluorophores can be exited in a 
cellular environment very near the plasma membrane (within <100 nm) while intracellular 
fluorescence is reduced resulting in clear imaging of the contact area (Mattheyses, 2010; Axelrod, 
2001).  
 
LSECs are very thin at the T-cell-LSEC contact, and immunostained TCR and CD11a 
clusters in the membrane of naïve CD8 T cells can be excited by an evanescent wave 
that penetrates the LSECs. Using TIRF microscopy we also found single non-
overlapping TCR and CD11a clusters at the T-cell/LSEC interaction plane, 
confirming the confocal data, which showed that a multifocal immune synapse is 
formed. Furthermore, PD-L1/PD-1 signaling did not alter the type of synapse and it 
did not change over the time period analyzed (Fig. 9A).  
We further investigated the average cluster size of the TCR and CD11a clusters by 
means of autocorrelation analysis (see Material and Methods) (Fig. 9B). Here, we 
could not detect differences in cluster size of either molecule analyzed in synapses 
including PD-L1-dependent signalling or in synapses without (Fig. 9C). In addition, 
we did not observe differences in cluster density in the T cell membrane upon LSECs 
interaction (Fig. 9D).  
Taken together, the TIRF microscopy data indicate that although LSEC-mediated PD-
L1-dependent signals lead to early changes in downstream TCR signaling events in 
naïve CD8 T cells, it does not affect the phenotype of the immune synapse formed 
between LSECs and T cells. 
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Figure 9. TCR and CD11a distribution in naïve CD8 T cell/LSEC interaction is not 
affected by PD-L1-dependent signals. 
A: OVA-loaded B6 and PD-L1 (B7H1)-/- LSEC were cultured with naïve OT-1 CD8 T cells and after the 
indicated times cells were fixed and stained for TCR and CD11a and analysed by TIRF microscopy. 
Scale bar shows 6 m. B: TCR and CD11a cluster sizes were examined by autocorrelation analysis: 
the approximate average half object size is proportional to the pixel shift leading to a correlation 
coefficient of 0.5 (n = 5 cells; values are given as mean ± SD; one pixel corresponds to 83.3 nm). C: 
Statistical analysis of B. D: Clusters were counted within a 14,051m2 area/T cell and cluster density 
is given as clusters per m2 (n=5). Data are representative for 3 independent experiments. Data are 
shown as mean +/- SD. Significance was calculated by Student t-test. *p0.05. 
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4.2. PD-L1/PD-1 signaling represses IL-2 production by LSEC-stimulated CD8 T 
cells 
It was previously discovered that CD8 T cells, which had been primed in the liver 
under noninflammatory conditions by antigen-presenting LSECs develop 
nonresponsiveness, and are thus not able to perform immediate cytotoxic functions 
or to produce cytokines (Diehl et al., 2008; Böttcher et al., 2013). Furthermore, CD8 
T cells primed by PD-L1-/- LSEC produce more IL-2 in comparison to CD8 T cells 
primed by B6 LSEC, indicating the role of PD-L1 in dampening of IL-2 production 
(Schurich et al. 2010; Diehl et al., 2008). To confirm that PD-L1-mediated effects 
were induced via PD-1 signaling we co-cultured PD-1-/- OT-I T cells with OVA-loaded 
LSECs and analyzed cytokine production by ELISA (Fig 10A). Indeed, we observed 
increased levels of IL-2 and IFNγ when PD-1 on T cells was lacking. Similarly, 
increased IL-2 production by T cells was observed when PD-L1 on LSECs was 
lacking (Fig. 10B).  
These results suggest that LSECs utilize the regulatory PD-L1/PD-1 signaling 
pathway to dampen IL-2 production by CD8 T cells, thereby preventing their full 
activation. 
 
 
 
Figure 10. PD-L1/PD-1 signaling suppresses IL-2 production in LSEC-primed T cells. 
A: Wild type or PD-1-/- OT-1 CD8 T cells were cultured with B6 LSEC for 4 days and restimulated with 
plate-bound anti-CD3 antibodies. After 24h IL-2 and IFN content in the supernatant was 
determined by ELISA. B: OT-1 CD8 T cells were cultured with antigen-presenting LSEC from B6 or 
PD-L1 (B7H1)-/- mice for the indicated times and the IL-2 concentration in the supernatant was 
determined by ELISA at the indicated time points. Data are depicted as mean +/- SEM. Data are 
representative from 3 independent experiments. Significance was calculated by ANOVA. **p0.01, 
***p0.001.  
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4.3 Co-stimulatory CD28 signaling does not prevent LSEC-mediated CD8 T cell 
non-responsiveness after prolonged co-inhibitory PD-L1/PD-1 signaling 
Initially, LSEC-stimulated CD8 T cells upregulate costimulatory markers and 
proliferate to the same extent as CD8 T cells primed by DC. Nevertheless, they do not 
sustain the expression of activation markers but downregulate it with time (Diehl et 
al., 2008; Böttcher et al., 2014). In order to investigate whether this phenomenon 
was dependent on co-stimulatory/inhibitory signaling, we investigated the kinetics 
of the IL-2 receptor, CD25 on T cells primed by wild type LSECs PD-L1-/- LSECs and 
DCs (Fig. 11A). We could observe that CD25 expression on T cells activated by PD-
L1-/- LSECs and DCs remains high in contrast to T cells activated by wild type LSECs 
where CD25 expression is downregulated within 48h. It has been reported that CD8 
T cells require sustained TCR signaling to fully develop into functional effector cells 
with sustained CD25 expression (van Stipdonk et. al., 2003). In contrast, CD8 T cells 
that received brief TCR stimulus were less receptive to IL-2 (CD25 expression 
decreased after 24h) and less efficient in killing (van Stipdonk et. al., 2003).  
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Figure 11. CD28 co-stimulation cannot reverse the induction of LSEC-primed CD8 T 
cells after PD-1 signal integration over time. 
A: OT-1 CD8 T cells were co-cultured with antigen-presenting B6, PD-L1 (B7H1)-/- LSEC or B6 DC for 
the indicated times and stained for CD8 and CD25. Grey filled lines: isotype control, black lines: CD25. 
Histograms show viable CD8 T cells. Numbers indicate geometric mean of CD25. B: OT-1 CD8 T cells 
were co- cultured with antigen-presenting LSEC for 4 days, after which they were restimulated with 
PMA/ionomycin and 4 h later stained for CD8 and IFNγ. Anti-CD28 antibodies (10 mg/ml) or isotype 
control antibodies were added to the co-cultures at the indicated times. Bar graph shows percentages 
of IFNγ-producing CD8 T cells upon restimulation at day 4 after CD28 abs or control abs were added 
at the indicated times. C: OT-1 CD8 T cells were co- cultured with antigen-presenting LSEC for 4 days, 
after which they were stained for CD8 and CD25. Anti-CD28 antibodies (5 mg/ml) or isotype control 
antibodies were added to the co-cultures at the indicated times. Histograms show CD25 expression 
on viable CD8 T cells, black line: with anti-CD28; filled grey: with control antibody; dotted: unstained. 
Bar graph shows CD25 mean fluorescence intensity at day 4 on viable CD8 T cells co-cultured with 
LSEC and anti-CD28 antibodies added at the indicated times. Representative data of 3 independent 
experiments are shown. Data are depicted as mean +/- SD. Significance was calculated by student t-
test. *p0.05, **p0.01, ***p0.001. 
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PD-1 expression on LSEC-primed CD8 T cells is sustained for at least 5 days (Fig. 
6C), indicating that LSEC-primed T cells stay receptive to co-inhibitory signaling for 
the whole period of time. Therefore, we hypothesized that the LSEC-mediated 
unique differentiation of naïve CD8 T cells requires integration of co-inhibitory 
signals over time. To investigate this, we attempted to prevent the induction of an 
LSEC-primed state in CD8 T cells by adding co-stimulatory anti-CD28 antibodies to 
the CD8 T cell-LSEC co-culture at different time points during co-culture. After 4 
days CD25 expression and IFNγ production by CD8 T cells was assessed (Fig 11B 
and C). When co-stimulation through CD28 was provided at early time points (0h or 
24h), CD8 T cells expressed CD25 and produced IFNγ, thus nonresponsiveness has 
been prevented. However, when CD28 co-stimulation was provided at 36h into the 
co-culture, CD8 T cells were not able to produce IFNγ upon restimulation. Overall, 
lack of cytokine production correlated with the lack of CD25 expression.  
Taken together, these results indicate that co-inhibitory PD-1 signals in LSEC-
primed T cells are integrated within 24 hours. After this time CD28 co-stimulatory 
signals cannot prevent the induction of nonresponsiveness of CD8 T cells primed by 
LSECs.  
 
4.4 Expression of small GTPase Arl4d in LSEC-primed CD8 T cells is PD-L1-
dependent 
Priming of naïve CD8 T cells by LSECs leads to development of T cells that are unable 
to perform effector function (Limmer et al., 2000). We could show that this unique 
state of CD8 T cells primed by LSECs is PD-L1/PD-1-dependent. In our group, gene 
expression analysis of in vitro generated LSEC-primed and DC-primed CD8 T cells 
was performed. Fig. 12 shows exemplary genes involved in T cell function, such as 
CD25 (IL-2Rα), CD122 (IL-2Rβ), granzyme B, IFNγ, T-bet, neuropilin 1 and Eomes. 
Genes involved in T cell activation (CD25, CD122, IFNγ, granzyme B) were not 
detected in LSEC-primed T cells, confirming previous findings that these cells are 
quiescent (Diehl et al. 2008, Böttcher et al., 2013). Moreover, we observed 
upregulation of Eomes expression, confirming the data of Böttcher et al. that LSEC-
primed CD8 T cell show memory-like phenotype. Interestingly, one of the gene 
significantly induced in LSEC-primed T cells was the small GTPase Arl4d, however, 
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its function in T cells remains to be elucidated.  
 
Figure 12. Arl4d expression is not detected in DC-stimulated CD8 T cells but 
upregulated in LSEC-primed CD8 T cells. 
Naïve OT-I CD8 T cells were cocultured with OVA-loaded LSEC or DC for 4 days. Cells were harvested 
and gene expression analyzed as described in the materials & method section. Graph shows the 
relative expression of the indicated genes. 
 
In order to validate the induction of Arl4d, we co-cultured CD8 T cells with B6 
LSECs, PD-L1-/- LSECs and DCs and performed real-time PCR analysis. We observed 
a significant increase in expression of the small GTPase, Arl4d in nonresponsive B6 
LSEC-stimulated CD8 T cells as compared to activated DC-stimulated CD8 T cells 
(Fig. 13). The induction of Arl4d mRNA did not occur in T cells stimulated by PD-L1-
/- LSECs suggesting that Arl4d expression is induced in LSEC-primed CD8 T cells in a 
PD-L1-dependent fashion. 
 
 
 
Figure 13. PD-L1-dependent expression of Arl4d in LSEC-primed CD8 T cells. 
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Naïve OT-I CD8 T cells were coculture with OVA-loaded B6 LSEC, PD-L1 (B7H1)-/- LSEC and DC for 
the indicated time points. Graph show mRNA Arl4d levels relative to naïve T cell mRNA levels (which 
were set as 1). Data are depicted as mean +/- SEM. Significance was calculated by student t-test. 
**p0.01, ***p0.001. 
 
These data suggest that Arl4d could be differentially expressed in naïve, 
nonresponsive and activated CD8 T cells. To confirm our results, we stimulated in 
vitro naïve CD8 T cells with anti-CD3 and anti-CD28 antibodies for indicated time 
points and performed real-time PCR for Arl4d (Fig. 14). Again, the data analysis 
revealed a downregulation of Arl4d mRNA in stimulated CD8 T cells in comparison 
with naïve CD8 T cells. Taken together, in vitro co-culture and antibody-stimulation 
results suggest that upon delivery of co-inhibitory signals by LSECs, Arl4d 
expression is upregulated. In contrast, upon delivery of co-stimulatory signals by DC, 
PD-L1-deficient LSECs or anti-CD3/CD28 antibodies in vitro, Arl4d expression is 
downregulated. 
 
 
Figure 14. Arl4d expression is downregulated in activated CD8 T cells. 
Naïve CD8 T cells were cultured on coated plate with anti-CD3 (2 μg/ml) and anti-CD28 (10 μg/ml) 
for the indicated time points. Graph shows Arl4d mRNA levels relative to naïve T cell mRNA levels 
(set as 1). Data are depicted as mean +/- SEM. 
 
4.5 The Arl4d knockout mouse serves as a proper tool to study small GTPase 
function 
As mentioned above, PD-L1/PD-1 signaling decreased CD8 T cell activation, 
cytotoxicity and inhibited IL-2 production. Interestingly, our findings on Arl4d 
expression (Fig. 12 and 13) suggest that Arl4d is induced downsteram of co-
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inhibitory PD-L1/PD-1 signaling. So far Arl4d has been reported to regulate actin 
remodeling via Arf6 and cytohesin-2, it can be targeted to the mitochondria where it 
alters mitochondrial membrane potential or it can participate in neurite formation 
(Li et al. 2007; Li et al. 2012; Yamauchi J. et al. 2009). However, to date there are no 
data concerning the role of Arl4d in T cell function.  
In order to investigate in detail the role of Arl4d in CD8 T cell immune regulation in 
vitro and in vivo, we obtained the Arl4dtm1a(EUCOMM)Wtsi mouse strain, which was 
generated by the Welcome Trust Sanger Institute in United Kingdom (Fig 15). 
Heterozygous mice obtained from the Sanger Institute were further bred to produce 
homozygous Arl4d knockout mice, which were used to study the role of Arl4d in 
CD8 T cell function. 
 
 
 
 
Figure 15. Schematic view of the "knock-out first" Arl4dtm1a(EUCOMM)Wtsi allele. 
Arl4d gene has been targeted by insertion of the L1L2_gt0 cassette, composed of FRT-flanked 
lacZ/neomycin sequence, in chromosome 11 upstream of the critical exon. Additionally, loxP sites 
flank the critical exon (Welcome Trust Sanger Institute, MGI Direct Data Submission. 2010).  
 
First, we characterized these mice in steady state and analyzed the lymphoid 
compartment. For this purpose, splenocytes from Arl4d-/- and wild type mice were 
stained for CD4 and CD8 and analyzed by flow cytometry. We found that the 
distribution of CD4 and CD8 T cells in the spleen of Arl4d knockout animals was 
comparable with wild type controls (Fig 16A). Moreover, also CD8 T cell percentages 
in the blood of Arl4d-deficient mice were not altered (Fig. 16B). As shown in Fig. 13, 
Arl4d expression depends on co-inhibitory PD-L1 signaling. PD-L1- and PD-1-
deficient mice develop autoimmunity, therefore, it was important to study whether 
Arl4d-deficiency already influences the activation state of T cells in steady state. 
Therefore, we stained for commonly used surface markers to distinguish naïve from 
activated or memory CD8 T cells: CD44, CD25 (IL-2 receptor) and CD62L (L-
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selectin). Expression levels of CD62L, a marker for naïve and central memory T cells, 
as well as the activation markers, CD44 and CD25 did not reveal major differences 
between Arl4d-deficient CD8 T cells and wild type CD8 T cells (Fig 16C, D and E). 
Taken together these data indicate that Arl4d deficiency neither affects the 
distribution nor the phenotype of CD8 T cells under homeostatic conditions. 
 
Figure 16. Arl4d-deficiency has no impact on CD8 T cell phenotype in steady state. 
A: Arl4d-deficient and wild type splenocytes were stained for CD4 and CD8 and shown as 
percentages of live cells. Representative plots of one mouse from three are shown. B: Bar graph show 
percentages of CD8 T cells among live cells in the spleen and blood. C: Splenocytes were stained for 
CD8, CD44 and CD62L. The histograms show CD44 (left) and CD62L (right) expression on CD8 T cells. 
Dotted line shows wild type and filled gray line knockout splenocytes. D: Bar graphs show CD44 (left) 
and CD62L (right) geometric mean. E: Splenocytes were stained for CD8 and CD25. The histogram 
shows CD25 expression on CD8 T cells. Bar graph shows geometric mean of CD25. Data are shown as 
mean +/- SEM. Three mice per group were analysed. Data are representative for at least 2 
independent experiments. 
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4.6 Arl4d deficiency leads to enhanced anti-viral CD8 T cell immune response 
4.6.1 Arl4d dampens IL-2 production in CD8 T cells in vitro 
LSEC-mediated nonresponsiveness of CD8 T cells depends on PD-L1 signaling, due 
to attenuation of IL-2 production (Diehl et al., 2008; Schurich et al., 2010). 
Interestingly, we could show that Arl4d expression is induced in LSEC-stimulated 
CD8 T cells and its expression is dependent on PD-L1 signals (Fig. 13). Based on 
these findings, we next investigated whether Arl4d plays a role in dampening of IL-2 
production in CD8 T cells. For this purpose, naïve wild type and Arl4d-/- CD8 T cells 
were stimulated with plate-bound anti-CD3 and anti-CD28 antibodies for 48 hours. 
Supernatants were collected after 24 and 48 hours and ELISA was performed to 
assess the IL-2 production. We observed an increased production of IL-2 by Arl4d-
deficient CD8 T cells compared to wild type CD8 T cells (Fig. 17). These data indicate 
that via induction of Arl4d, IL-2 production is inhibited in stimulated CD8 T cells in 
vitro.  
 
 
Figure 17. Arl4d deficiency leads to enhanced IL-2 production. 
Arl4d-/- and wild type CD8 T cells were stimulated with anti-CD3 (2 μg/ml) and anti-CD28 (10 μg/ml) 
for the indicated time points. Data are shown as mean +/- SD. Graph show representative data from 
one out of two independent experiments. Statistical significance was calculated by Student’s t-test. 
*p0.05 , ***p0.001. 
 
4.6.2 Arl4d attenuates primary anti-viral CD8 T cell immunity in vivo 
IL-2 plays an important role in CD8 T cell immune responses (Malek, 2008). It can 
drive development of naïve CD8 T cells into effector and memory cells upon antigen 
stimulation (Joshi et al., 2007; Pipkin et al., 2010; Liao et al., 2013). 
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To evaluate whether the increased IL-2 production by Arl4d-deficient CD8 T cells in 
vitro (Fig. 18) has an impact on the generation of a local immune response in vivo, 
we sorted either CD45.2+ Arl4d-deficient or CD45.2+ wild type naïve OT-I CD8 T cells 
and adoptively transferred them into CD45.1 congenic animals. Importantly, 
different congenic markers on transferred (CD45.2) and endogenous (CD45.1) CD8 
T cells allow tracking transferred T cells during analysis. One day after transfer 
CD45.1 animals were infected with a non-replicating recombinant adenovirus 
expressing ovalbumin, GFP and luciferase (AdGOL) that preferentially infects 
hepatocytes. Starting from day 0 we studied accumulation of the transferred CD8 T 
cells in the blood by flow cytometry. Both Arl4d-deficient and wild type transferred 
CD8 T cells started to recirculate in the blood of AdGOL infected animals from day 3 
onward. Both an increased total number and percentages of CD45.2+ Arl4d-deficient 
CD8 T cells as compared to wild type CD8 T cells was found, starting from day 4 till 
day 8, indicating increased expansion of Arl4d-deficient CD8 T cells in the blood in 
response to viral infection (Fig. 18A and B). 
During infection naïve antigen-specific CD8 T cells expand and differentiate into 
effector cells (Joshi et al., 2007). Moreover, it has been shown that IL-2 signals 
during primary immune response affect differentiation of CD8 T cells into short-
lived effector cells (SLEC) (Pipkin et al., 2010). As we observed that Arl4d affects IL-
2 production in vitro, this led us to examine whether Arl4d could affect effector T 
cell differentiation in vivo. For this reason, we analyzed the accumulation of KLRG1+ 
(a marker for SLEC) CD8 T cells in the blood of infected mice. Indeed, we found that 
a higher percentage of transferred Arl4d-deficient T cells expressed KLRG1+ as 
compared to the wild type controls starting at day 4 until day 8 after infection (Fig. 
18C). Hence, Arl4d deficiency leads to enhanced development of effector T cells 
early during infection. 
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Figure 18. Increased expansion of Arl4d-deficient CD8 T cells in the blood during viral 
infection. 
8*105 CD45.2+ Arl4d-deficient or wild type CD8 T cells were adoptively transferred into CD45.1 
congenic animals. One day after transfer, mice were infected with AdOVA (5*106 PFU/mouse). A: 
Blood of CD45.1 infected mice was taken every day starting from day 0 and the cells were stained for 
CD8 and CD45.2 and analyzed by flow cytometry. Representative plots show CD45.2+ CD8 T cells 
accumulation in the blood of one mouse per group at day 7 and day 8. Numbers indicate percentages. 
B: Total numbers of transferred CD45.2+ either Arl4d ko or wild type CD8 T cells were analysed by 
flow cytometry in the blood of CD45.1+ infected mice at indicated times. C: Blood cells from B were 
stained additionally for KLRG1 and analysed by flow cytometry. Graph shows percentages of CD45.2+ 
SLEC in the blood of CD45.1 infected mice. Data from one experiment with 4 mice per group are 
shown. Data are presented as mean +/- SEM. Significance was calculated by Student’s t-test. *p0.05, 
**p0.01, ***p0.001. 
 
To determine the expansion, phenotype and function of the transferred T cells in the 
organs, CD45.1 mice were sacrificed eight days after AdGOL infection and spleens 
and livers were collected for analysis. Similar to the results obtained from the blood 
(Fig. 18B), increased amounts of transferred Arl4d-deficient CD8 T cells 
accumulated in the liver at day 8 after AdGOL infection (Fig. 19A). Additionally, we 
found increased amounts of Arl4d-deficient T cells in the spleen as compared to wild 
type T cells (Fig. 19B). Thus, Arl4d-deficiency not only leads to enhanced expansion 
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of CD8 T cells in the blood, but also in spleen and liver eight days after viral 
infection, indicating that Arl4d functions to restrict effector T cell generation in vivo. 
 
Figure 19. Arl4d dampens IL-2 production in vivo. 
A: At day 8 liver-associated lymphocytes and splenocytes were stained for CD8 and CD45.2 and 
analyzed by flow cytometry. Bar graph show total number of CD45.2+ cells per organ. B: At day 8 
splenocytes were stained and analysed as in A. Bar graph show total number of CD45.2+ cells per 
organ. C: Splenocytes were restimulated or not with PMA/Ionomycin for 4 hours and stained for CD8, 
CD45.2 and IL-2. Bar graph show percentages of IL-2 producing CD45.2+ CD8 T cells. Data from one 
experiment with 4 mice per group are depicted. Data are shown as mean +/- SEM. Significance was 
calculated by Student’s t-test. *p0.05, **p0.01, ***p0.001. 
 
To determine the functionality of Arl4d-deficient and wild type CD8 T cells after 
AdGOL infection, splenocytes were restimulated with PMA/Ionomycin for 4 hours. 
We observed that Arl4d-deficient CD8 T cells produce increased amounts of IL-2 
upon restimulation compared to wild type controls (Fig 19C), indicating that Arl4d 
regulates IL-2 production not only in vitro (Fig. 17), but also in vivo. 
In summary, these data demonstrate that Arl4d inhibits expansion of virus-specific 
CD8 T cells. Moreover, Arl4d limits effector CD8 T-cell development and IL-2 
production in response to viral infection.  
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To further investigate whether Arl4d-deficiency conveys an advantage in 
competition with Arl4d proficient T cells under the same inflammatory conditions, 
we co-transferred equal amount of Arl4d-/- and wild type naïve CD8 T cells into one 
recipient mouse before infection with AdGOL. 
Therefore, we sorted CD45.1+ Arl4d-deficient and B6 Thy1.1 (CD90.1+) wild type 
naïve OT-I CD8 T cells and adoptively transferred them in a 1:1 ratio into a single 
C57BL/6 (CD45.2+, CD90.2+) recipient. Of note, one additional congenic marker 
(CD90.1) on the wild type CD8 T cells had to be used in order to enable tracking of 
transferred wild type and knockout CD8 T cells in one animal. Again, one day after 
the T cell transfer, C57BL/6 mice were infected with AdGOL. Additionally, one group 
of mice was transferred with T cells but left non-infected, to confirm that transferred 
cells could only expand upon the antigen encounter.  
In the previous experiment, we had observed that transferred CD8 T cells appeared 
in the blood at day 3 after infection. Therefore, we started to investigate 
accumulation of the transferred cells in the blood of infected and non-infected mice 
from day 3 onward. In contrast to the non-infected control group, both Arl4d-
deficient and wild type transferred CD8 T cells started to recirculate in the blood 
upon AdGOL infection (Fig. 20A). Interestingly, we found increased percentages (Fig. 
20B) and total numbers (Fig. 20C) of CD45.1+ Arl4d-deficient CD8 T cells as 
compared to wild type CD90.1+ CD8 T cells starting from day 3 till day 8, suggesting 
stronger expansion potential of knockout cells in competition with wild type cells in 
the blood of AdGOL infected mice. Additionally, transferred CD8 T cells in the blood 
of non-infected control mice did not proliferate, as expected. 
These data confirm our previous finding that Arl4d-deficiency leads to increased 
expansion of CD8 T cells in the blood of viral infected mice. Importantly, the 
enhanced expansion of Arl4d-deficient CD8 T cells in response to infection is 
maintained in the presence of wild type cells that compete for the same antigen.   
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Figure 20. Arl4d-deficient CD8 T cells demonstrate a stronger potential for expansion 
in the blood in competition with wild type CD8 T cells in response to infection. 
5*105 CD45.1+ Arl4d-deficient and 5*105 CD90.1+ wild type OT-I CD8 T cells were mixed and 
adoptively transferred into B6 animals. One day after transfer, mice were infected with AdOVA (5*106 
PFU). A: Blood of B6 infected mice was taken every day starting from day 3 and the cells were stained 
for CD8, CD45.1 and CD90.1 and analyzed by flow cytometry. Representative plots show distribution 
of CD45.1 and CD90.1 transferred cells among CD8 T cells in the blood of one mouse per group at day 
3, 5 and 7. Numbers indicate percentages. B: Bar graph shows percentages of transferred either wild 
type (wt; CD90.1+) or Arl4d knockout (ko; CD45.1+) CD8 T cells in the blood of B6 infected mice at 
indicated time points after viral infection. C: Bar graph shows total number of transferred either wild 
type (wt; CD90.1+) or Arl4d knockout (ko; CD45.1+) CD8 T cells in the blood of B6 infected mice at 
indicated time points after viral infection. Data are shown as mean +/- SEM for n=3 mice in the non-
infected group and n=6 mice in the infected group and represent one out of two experiments. 
Significance was calculated by Student’s t-test. *p0.05, **p0.01, ***p0.001. 
 
To evaluate accumulation and distribution of transferred CD8 T cells in the organs, 
eight days after AdGOL infection, we sacrificed B6 mice from the infected and non-
infected groups and collected livers and spleens. As mentioned above AdGOL infects 
predominantly hepatocytes. Indeed, wild type and Arl4d-deficient CD8 T cells 
accumulated preferentially in the liver; 6,42 ± 0,47% vs. 23,37 ± 1,49% of wild type 
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CD8 T cells and 14,43 ± 0,85% vs. 55,67 ± 2,45% of Arl4d-/- CD8 T cells in the spleen 
and liver, respectively (Fig. 21A and B). Furthermore, compared to the wild type T 
cells, we found increased percentages and total numbers of Arl4d-deficient CD8 T 
cells at day 8 after infection in spleen and liver, confirming that Arl4d-deficiency 
also leads to increased expansion of CD8 T cells in periperal organs upon viral 
infection (Fig. 21B and C).  
 
 
Figure 21. Increased expansion of Arl4d-deficient CD8 T cells in the organs. 
Eight days after infection liver-associated lymphocytes and splenocytes were stained for CD8, CD45.1 
and CD90.1. A: Dot plots show distribution of wt (CD90.1+) and ko (CD45.1+) CD8 T cells in the spleen 
and liver of one representative infected mouse. B: Bar graphs show percentages of either wild type 
(wt; CD90.1+) or Arl4d knockout (ko; CD45.1+) CD8 T cells in the spleen and liver of non-infected and 
infected mice. C: Bar graphs show total numbers of the cells in B. per organ. Data are shown as mean 
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+/- SEM for n=3 mice in the non-infected group and n=6 mice in the infected group and represent one 
out of two experiments. Significance was calculated by Student’s t-test. *p0.05, **p0.01, 
***p0.001. 
 
4.6.3 CD8 T cells demonstrate enhanced ability for effector T cell 
differentiation in the absence of Arl4d 
It is well known that once CD8 T cell encounter their antigen, its differentiation into 
effector cells is initiated (Boulet et al., 2014). We wondered whether this 
phenomenon is maintained when both wild type and knockout CD8 T cells compete 
for the same antigen during viral infection. To assess the effector CD8 T cell 
development in this situation we investigated the accumulation of KLRG1+ cells in 
the blood, starting from day 3 till day 8, and in the spleen and liver 8 days after 
AdGOL infection. To specifically examine the SLEC we included CD127 in the 
staining and we defined SLEC to be the KLRG1+ and CD127- population (Kaech et al., 
2003; Joshi et al. 2007) (Fig. 22A).   
In the blood of AdGOL-infected mice, numbers of KLRG1+CD127- cells among 
transferred Arl4d-deficient T cells were increased compared to wild type CD8 T cells 
in the blood (Fig. 22B). Again, similar results were obtained from the spleen and 
liver (Fig. 22C and D). Together, these data demonstrate that Arl4d limits SLECs 
development during a viral CD8 T cell response.  
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Figure 22. Arl4d inhibits effector T cell differentiation upon viral infection. 
A: Gating strategy for the SLEC population identification. SLEC: CD8+CD90.1+/CD45.1+ KLRG1+CD127-
. B: Bar graphs show percentages (left panel) and total number (right panel) of SLEC in the blood. Bar 
graphs show percentages (left panel) and total number (right panel) of SLEC 8 days after AdOVA 
infection per spleen: C. and liver: D. Data are shown as mean +/- SEM for n=3 mice in the non-infected 
group and n=6 mice in the infected group and represent one out of two experiments. Significance was 
calculated by Student’s t-test. *p0.05, **p0.01, ***p0.001. n.d – not detected. 
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Figure 23. Arl4d dampens IL-2 and IFNγ production by CD8 T cells after 
restimulation. 
Eight days after AdOVA infection splenocytes and liver-associated lymphocytes were restimulated 
with PMA/Ionomycin for 4 hours. Total number of IL-2 (A) and IFNγ (B) producing transferred either 
wild type (wt; CD90.1+) or Arl4d knockout (ko; CD45.1+) CD8 T cells per spleen (left panel) and liver 
(right) are shown as mean +/- SEM of n=6 infected mice and represent one out of two experiments. 
Significance was calculated by Student’s t-test. *p0.05. 
 
 
Next, we wondered whether increased expansion and effector T cell development of 
Arl4d-deficient CD8 T cells would correlate with increased IL-2 production, as it has 
been previously showed. Indeed, we observed increased total number of IL-2-
producing Arl4d-deficient CD8 T cells after restimulation in both liver and spleen 
(Fig. 23A). In addition, we found increased total number of IFNγ-producing 
knockout CD8 T cells in liver and spleen as compared to the restimulated wild type 
CD8 T cells (Fig. 23B). These data indicate that Arl4d restricts the development of 
IL-2 and IFNγ producing T cells. 
In summary, we confirmed that Arl4d inhibits expansion and effector T cell 
differentiation of antigen-specific CD8 T cells in response to viral infection. 
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Furthermore, we could show that Arl4d limits the development of IL-2 and IFNγ 
producing CD8 effector T cells. 
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5 Discussion 
 
CD8 T cells primed by liver endothelial cells (LSECs) undergo a particular differentiation 
program. Initially activated, they develop into nonresponsive CD8 T cells with memory-
like phenotype (Diehl et al., 2008; Böttcher et al., 2013; Böttcher et al., 2014). Previously, 
our group discovered that this unique state of CD8 T cells depends on delivery of co-
inhibitory signaling (Diehl et al., 2008). In the present study, we further investigated the 
mechanism of CD8 T cell-LSEC interaction and could show that unique differentiation 
state of CD8 T cells requires integration of co-inhibitory PD-L1/PD-1 signaling over 
time, after which the nonresponsiveness of CD8 T cells cannot be prevented by CD28 co-
stimulation. Furthermore, we identified the small GTPase, Arl4d to be PD-L1-
dependently overexpressed in CD8 T cells primed by LSECs. Arl4d expression inhibits 
IL-2 production by T cells and thereby may regulate IL-2 availability. As it is PD-L1-
dependently induced it might be a new downstream signaling molecule of this 
important co-inhibitory signaling pathway. 
 
5.1 LSEC-CD8 T cell interaction results in multifocal synapse formation 
The function of the adaptive immune system is initiated by interaction of antigen 
presenting cell (APC) with T cells. Upon antigen-specific contact of T cell with APC an 
immunological synapse (IS) is formed at the interaction site. First reports showed that 
the immune synapse consists of a central cluster of pMHC-TCR interactions (cSMAC) 
surrounded by a peripheral ring of adhesion molecules (pSMAC), which is characteristic 
for a classical IS (Monks et al., 1998; Grakoui et al., 1999). However, recent studies on IS 
formation between different types of T cells and APCs revealed additional forms such as 
a multifocal IS and a kinapse (Dustin, 2009). The type of IS depends on T cell 
differentiation state, type of APC interacting with T cell or the function of synapse 
(Thauland and Parker, 2010). 
The classical synapse (bull’s eye) is observed mostly during CTL or NK cell interaction 
with target cells (Krzewski and Storminger, 2008; Stinchcombe and Griffiths, 2003). In 
this type of IS, the cytokine granules are released in the cSMAC, whereas the pSMAC act 
as a gasket for efficient delivery of the lytic granules to the target cell (Beal et al., 2008; 
Beal et al., 2009), indicating that the type of IS is correlated with the function. In the 
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present study, we investigated the formation of the immunological synapse between 
antigen-presenting LSECs and naïve CD8 T cells. As CD8 T cells primed by LSECs do not 
become activated but develop into nonresponsive CD8 T cells that do not produce 
cytokines (Diehl et al., 2008; Schurich et al., 2010; Böttcher et al., 2013), we did not 
expect a bull’s-eye synapse. Indeed, we did not observed a central ring of TCRβ (cSMAC) 
surrounded by CD11a ring (pSMAC) at the contact site of CD8 T cells and LSECs but 
several clusters of TCRβ and CD11a spread across the contact area, indicating a 
multifocal synapse (Fig. 6 and Fig. 9). The multifocal type of IS was initially described in 
double-positive thymocytes interacting with planar bilayers, in contrast to mature T 
cells that formed the classical IS on such bilayers. Those studies showed that the type of 
IS depends on TCR signal strength (Richie et al., 2002; Hailman et al., 2002). The fact 
that TCR proximal signaling is inhibited upon CD8 T cell priming by LSECs (Fig. 6) and 
liver-primed CD8 T cells do not produce cytokines could explain the multifocal synapse 
formation. However, there are several contradictory reports showing that multifocal 
synapse is formed between naïve CD4, CD8 and activated CD4 T cells with DCs (Brossard 
et al., 2005; Fisher et al., 2008; Alarcon et al., 2011; Tseng et al., 2008), in cases of strong 
TCR signaling. This indicates that T cells do not require a classical IS for full activation 
(Thauland and Parker, 2010). Furthermore, the bull’s-eye synapse is not only formed as 
a cytotoxic synapse as this type of IS has been also observed between CD4 T cells and B 
cells forming an inhibitory synapse (Reichardt et al., 2007). That would suggest that not 
only T cell differentiation state, type of APC and TCR signal strength alone but probably 
all conditions together play a role in the IS formation.  
As T cells are highly motile and continuously scan secondary lymphoid organs in order 
to detect an antigen, they can also form asymmetric motile junctions with APCs, called 
immunological kinapses (Dustin, 2009). However, although naïve CD8 T cells migrate 
intensively across LSECs in vitro in the absence of antigen, they stop migrating and 
remain arrested immediately after antigen-specific recognition on MHC I molecules on 
LSECs (von Oppen et al., 2009). Therefore, as expected, antigen-specific interaction of 
CD8 T cells and LSECs and did not lead to kinapse formation.  
Taken together, the interaction between antigen-presenting LSECs and naïve CD8 T 
cells, which leads to silencing of immediate effector function in CD8 T cells, results in the 
formation of a multifocal immune synapse. 
 
Discussion 
 
75 
 
 
5.2 The multifocal immune synapse between LSEC-CD8 T cells is formed 
independently of PD-L1/PD-1  
Previous findings show that upon antigen-specific LSEC-CD8 T cell interaction, the 
expression of the co-inhibitory molecule PD-L1 on antigen-presenting LSECs was 
upregulated, however no upregulation of co-stimulatory molecules CD80 and CD86 was 
observed. In the absence of PD-L1 on LSECs, CD8 T cells acquired full effector function 
and produced IL-2 upon restimulation, indicating that PD-L1 signals are required for 
CD8 T cell nonresponsiveness (Diehl et al., 2008). To further analyze this mechanism, we 
investigated PD-1 expression kinetics on LSEC-primed CD8 T cells and found antigen-
specific induction of PD-1 expression early (1-4 hours) after LSEC stimulation (Fig. 6). 
Furthermore, consistent with the previous findings (Diehl et al., 2008) we showed that 
PD-L1/PD-1 signaling is required for CD8 T cell nonresponsiveness induced by LSEC-
priming (Fig. 10).  
In the immune synapse, PD-1 colocalizes with the TCR at the immunological synapse 
and forms PD-1-TCR microclusters, which are required for the inhibition of TCR 
proximal signaling (Pentcheva-Hoang et al., 2007; Yokosuka et al., 2012). This results in 
inhibition of CD3ζ and ZAP70 phosphorylation and subsequent attenuation of IL-2 
production (Sheppard et al., 2004; Parry et al., 2005). Our finding that liver-primed CD8 
T cells express PD-1 for at least 5 days and that PD-1 signaling attenuates TCR proximal 
signal strength (Fig. 6) led us to the assumption that PD-1 could have an impact on the 
immune synapse formation upon CD8-LSEC interaction. Therefore, we compared the IS 
formed between PD-L1-deficient (co-inhibitory signaling cannot be delivered) or B6 
LSECs and CD8 T cells. In contrast to studies mentioned in section 5.1 (Richie et al., 
2002; Hailman et al., 2002), we provide evidence that although PD-1 signals influenced 
TCR proximal signal strength, it did not influenced multifocal synapse formation (Fig. 7 
and Fig. 9). Although CD8 T cells primed by PD-L1-deficient LSECs become activated and 
produce cytokines (Fig. 10), they form the same type of IS as nonresponsive B6 LSEC-
primed CD8 T cells, indicating that the formation of multifocal IS upon CD8 T cell 
priming by LSECs is PD-L1/PD-1-independent. 
Our results are consistent with a work on NK cells, which showed that NK cells formed 
either a cytolytic or noncytolytic (inhibitory) synapse with target cells in in vitro 
systems. In both, polyclonal IL-2 activated NK cells interacting with autologous B 
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lymphoblastoid cell line (BLCL) leading to NK cell inhibition, and NK cells interacting 
with target cells lacked self-MHC molecules, which activates NK cells, a bull’s eye 
synapse was observed (Vyas et al., 2001; Dustin and Long, 2010). Surprisingly, 
nonresponsive liver-primed CD8 T cells form the same type of IS as activated DC-primed 
CD8 and CD4 T cells (Brossard et al., 2005; Dustin et al., 2006; Tseng et al., 2008). Hence, 
our and others findings indicate that the type of the synapse does not always correlate 
with the function.  
Although the phenotype of the IS formed at the contact site of CD8 T cells and LSECs was 
not influenced by PD-L1/PD-1 signaling, perhaps the individual microcluster of the 
multifocal immune synapse could be affected. TCR proximal signals are sustained in TCR 
microclusters formed at the IS periphery (Varma et al., 2006), and the size of these TCR 
microclusters has been shown to depend on the antigen concentration and further on 
TCR signal strength. In the presence of decreasing the antigen concentrations, the size 
and density of cSMAC were reduced (Yokosuka et al., 2005). Additionally, also the size of 
individual TCR microclusters was proportional to the density of pMHC presented on 
lipid bilayers (Yokosuka et al., 2005). In our experiments we did not titrate the antigen 
presented by LSECs, however we observed decreased proximal TCR signaling of LSEC-
primed CD8 T cells (as a result of PD-1 function) in comparison to CD8 T cells primed by 
PD-L1-deficient LSECs. Nevertheless, the reduced TCR signal strength, due to PD-1 
signaling, did not influenced cluster size or cluster count within multifocal immune 
synapse (Fig. 9), indicating that both size and density of individual microclusters in the 
multifocal synapse is not dependent on PD-L1/PD-1 signaling.  
In summary, our data indicate that although CD8 T cell stimulation by B6 or PD-L1-
deficient LSECs leads to different functional outcomes, such different signaling does not 
affect the phenotype of the immune synapse. 
We identify the multifocal synapse by staining of the cSMAC-associated molecule TCRβ 
and the pSMAC-associated molecule CD11a. However, we did not stain for other 
signaling molecules downstream from the TCR to analyze signal transduction within the 
synapse. Different signaling molecules are recruited to the inhibitory and cytolytic bull’s 
eye synapse in NK cells. Within the cSMAC of the inhibitory synapses Src homology 
domain 2-containing protein tyrosine phosphatase 1 (SHP-1) was abundant, whereas in 
the cytolytic synapses no SHP-1 but several tyrosine kinases (Lck, ZAP70) were detected 
(Vyas et al., 2001; Vyas et al., 2002; Dustin and Long, 2010). Similar to the inhibitory 
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interaction in NK cells, PD-1 can recruit Src homology domain 2-containing protein 
tyrosine phosphatase 2 (SHP-2), which results in dephosphorylation of TCR proximal 
signals (Yokosuka et al., 2012). As PD-1 signals are crucial to induce the particular 
differentiation state of LSEC-primed CD8 T cells (Fig. 10), it is possible that by 
promoting recruitment SHP-2, it affects the function of other molecules, like Lck, ZAP70 
or SLP-76 in the multifocal synapse at the CD8 T cell-LSEC interface.  
In summary, our data indicate that although CD8 T cell stimulation by wild type or PD-
L1-deficient LSECs leads to different functional outcomes, these different outcomes are 
not a result of alteration in immune synapse properties, but more likely due to signals 
further downstream of the TCR. 
 
5.3 LSEC-primed CD8 T cell state depends on the integration of co-inhibitory 
signaling over a certain period of time 
In the present work, we demonstrate that the differentiation state of LSEC-primed CD8 T 
cells depends on PD-L1/PD-1 signals. Although PD-1 can accumulate within the immune 
synapse and modulate TCR downstream signaling (Pentcheva-Hoang et al., 2007; 
Yokosuka et al., 2012), it did not affect the phenotype of the synapse or the size and 
density of clusters within the synapse formed between CD8 T cells and LSECs. As the 
immune synapse is formed within a minutes after cell-cell contact, we therefore 
supposed that these early events during priming do not play a role in the unique 
programming of liver-primed CD8 T cells. Our data show that CD8 T cells primed by 
LSEC upregulate PD-1 on the surface, which interacts with PD-L1 on LSECs (Diehl et al., 
2008), and sustain its expression for 5 days (Fig. 6). Hence, rather the longevity of 
signaling than the early priming might be important for the induction of nonresponsive 
state of liver-primed CD8 T cells.  
There are reports demonstrating that CD8 T cells need to receive sustained TCR 
signaling for a particular period (about twenty hours) of time in order to develop into 
fully differentiated effector cells and to acquire killing function (Berg et al., 1998; Iezzi et 
al., 1998; van Stipdonk et al., 2003). One study showed that not TCR engagement on CD8 
T cells alone but sustained TCR/CD3 stimulation is required to develop TCR 
downstream signaling (Berg et al., 1998), in order to start Akt signaling integration that 
enhances transcriptional program for effector CD8 T cell development (Kim et al., 2012). 
The others showed that naïve OT-I CD8 T cells stimulated with OVA for four hours did 
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not expand to the same extent as CD8 T cells stimulated for twenty hours and showed 
reduced killing activity (van Stipdonk et al., 2003). As CD8 T cells require integration of 
the signaling in order to develop into effector cells, we supposed that LSEC-primed CD8 
T cells in order to develop into nonresponsive state also could require integration of the 
inhibitory signaling during a distinct time period. 
CD8 T cells stimulated by antigen-presenting LSECs initially increase CD25 and CD44 
expression and downregulate CD62L expression and proliferate identical to CD8 T cells 
stimulated by DCs. However, they do not sustain activation marker expression and 
become CD25negCD62Lhigh within 5 days after initial stimulation (Diehl et al., 2008; 
Böttcher et al., 2014). In the presence of PD-L1/PD-1 signaling, downregulation of CD25 
expression on LSEC-primed T cells was completed within 48 hours (Fig. 11). In contrast, 
PD-1 expression was sustained for at least 5 days after reaching its maximum at 24 
hours (Fig. 6), indicating that LSEC-primed T cells stay receptive to inhibitory signaling 
throughout this time. Previous findings show that augmenting the level of IL-2 in LSEC-
CD8 T cell co-cultures, either by addition of exogenous IL-2 or anti-CD28 Abs at the start 
of co-culture, resulted in the full activation of LSEC-primed CD8 T cells (Diehl et al., 
2008; Schurich et al., 2010). In order to investigate whether LSEC-primed CD8 T cells 
required sustained co-inhibitory signaling to fully differentiate into nonresponsive CD8 
T cells, we added anti-CD28 Abs at different time points after initiation of LSEC-CD8 T 
cell interaction. Interestingly, we found that co-stimulation via CD28 failed to overcome 
the unique differentiation program of LSEC-primed CD8 T cells when introduced after 
36 hours of PD-1 signal integration (Fig. 11). Thus, the key events in LSEC-induced T cell 
differentiation occur within 36 hours. 
In summary, our studies demonstrate that development of the nonresponsiveness of 
LSEC-primed CD8 T cells requires integration of PD-L1/PD-1 signaling for 36 hours, 
after which this particular differentiation program cannot be reversed by CD28 co-
stimulatory signaling. 
 
5.4 PD-L1-dependent expression of newly discovered small GTPase in CD8 T cells 
Our study shows the importance of PD-1 signal integration in induction of a quiescent 
state of CD8 T cells primed by LSECs. In order to further characterize these unique cells, 
we investigated their gene expression profile. Our results of a gene array were 
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consistent with the findings of Böttcher et al. showing that LSEC-primed CD8 T cells, in 
contrast to DC-primed CD8 T cells, do not express key genes characteristic for cytotoxic 
T cells like granzyme B, T-bet, IFNγ and IL-2R (Fig. 12). Furthermore, we could confirm 
that LSEC-primed CD8 T cells upregulate Eomes, which is characteristic for memory T 
cells, and Neuropilin 1 expression (Fig. 12). Taken together, we confirmed previous 
findings showing that LSEC-primed CD8 T cells are quiescent and display a memory-like 
phenotype (Diehl et al., 2008; Schurich et al., 2010; Böttcher et al., 2013). Furthermore, 
our analysis identified the small GTPase, Arl4d to be overexpressed in LSEC-primed CD8 
T cells, whereas its expression in DC-primed CD8 T cells was absent, which we 
confirmed by RT PCR analysis. We further found that Arl4d is expressed in steady state 
in naïve CD8 T cells and upon LSEC priming its expression increases, whereas upon DC 
priming or antibodies stimulation it decreases (Fig. 13 and Fig. 14). Moreover, we 
observed that Arl4d expression in liver-primed CD8 T cells to be PD-L1 dependently 
induced (Fig. 13). These findings revealed that this newly discovered molecule might 
play a role in PD-L1/PD-1 signaling. 
 
PD-1 inhibitory function results in attenuation of downstream signaling and dampening 
of IL-2 production (Francisco et al., 2010; Dai et al., 2014). SHP-2 is recruited to PD-1 on 
PD-1-PD-L1 binding and dephosphorylates CD3ζ, ZAP70 and further downstream PLCγ1 
and ERK (Sheppard et al., 2004; Yokosuka et al., 2012). Furthermore, PD-1 inhibits 
PI3K/Akt pathway responsible for IL-2 transcription and IL-2 production (Parry et al., 
2005). Here, we find that Arl4d, similar to PD-1, dampens IL-2 production by stimulated 
CD8 T cells (Fig. 17). However, how Arl4d achieves this, it requires further investigation. 
Considering the molecular structure of the Arl4d GTPase, there are several possible 
ways in which this molecule may influence T cell function via PD-1-dependent 
repression of IL-2 synthesis. Arl4d is a small GTPase and can exist as a GTP- and a GDP-
bound form, which in other GTPases is essential for its function. It further possesses a 
nuclear localization signal (NLS) for targeting to the nucleus and a myristoylation site 
for targeting to the plasma membrane. In its active form (GTP-bound), Arl4d has been 
reported to modulate actin remodeling by recruiting cytohesin-2 to the plasma 
membrane. Thereby, it indirectly activates Arf6, which is followed by actin 
reorganization and subsequent cell migration (Li et al., 2007; Hofmann et al., 2007; 
Yamauchi et al., 2009). In contrast, we have found Arl4d upregulation in liver-primed 
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CD8 T cells, which are arrested on LSECs upon antigen recognition (von Oppen et al., 
2009). Furthermore, PD-1 is shown to promote CD4 T cell in vivo migrating upon 
antigen-specific interaction (Fife et al., 2009). In contrast, we showed upregulation of 
PD-1 expression in CD8 T cells which stop migrating upon antigen binding. These 
contradictory results could be explained by the fact that different cell types were 
investigated in different in vitro and in vivo systems. We investigated here antigen-
specific stimulation of primary CD8 T cells with LSECs, whereas other investigated HEK 
293T cell line (Li et al., 2007) and N1E-115 neuroblastoma cell line (Yamauchi et al., 
2009) transfected with Arl4d constructs or in vivo stimulation of CD4 T cells (Fife et al., 
2009). 
The switch between a GDP-bound to a GTP-bound form of all small GTPases is catalyzed 
by guanine exchange factors (GEFs), cytohesins (Kolanus, 2007; Donaldson and Jackson, 
2011). Cytohesin-2 and cytohesin-3 showed opposite impact on cell migration. 
Knockdown of cytohesin-2 resulted in reduction of cell migration, whereas knockdown 
of cytohesin-3 resulted in enhancement of cell migration (Oh and Santy, 2010). 
Cytohesin-3 is reported to be upregulated in anergic CD8 T cells that do not produce 
cytokines (Korthäuer et al., 2000). Arl4d recruits cytohesin-2 to the plasma membrane 
and indirectly promote migration (Li et al., 2007). The fact that Arl4d is upregulated in 
nonresponsive CD8 T cells, which do not produce IL-2, led us to the assumption that in 
this situation it recruits cytohesin-3, instead of cytohesin-2, and that could explain the 
migration stop of LSEC-primed CD8 T cells. However, it requires further investigation. 
 
The GTP-bound form of Arl4d functions at the plasma membrane, whereas the GDP-
bound form has been reported to localize to the cytosol or the nucleus (Li et al., 2007; 
Hofmann et al., 2007). Furthermore, Arl4d GDP-bound form has been also found in the 
mitochondrial inner memebrane (Li et al., 2012), one could speculate that it could 
interfere with T cell activation and IL-2 production via inhibition of mitochondrial 
function. The TCR-induced generation of mitochondrial reactive oxygen species (mROS) 
is crucial for T cell activation in both CD4 and CD8 T cells by activating the nuclear factor 
of activated T cells (NFAT) that is required for IL-2 induction (Kaminski et al., 2010; 
Sena et al., 2012). ROS are produced in the process called mitochondrial oxidative 
phosphorylation (OXPHOS) at the Complex III located at the inner mitochondrial 
membrane (Marchi et al., 2012). Interestingly, the inactive form of Arl4d (GDP form) 
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translocates to the mitochondrial inner membrane and causes disruption of the 
membrane potential followed by mitochondrial fragmentation (Li et al., 2012), which 
impairs mitochondrial function and could potentially interfere with ROS production. 
Such reduction of mitochondrial membrane potential can also cause a decrease in IL-2 
mRNA expression (Sena et al., 2013). Thus, in its GDP-bound form Arl4d could indirectly 
inhibit IL-2 production by altering mitochondrial function.  
Upon T cell activation, the co-stimulatory molecule CD28 plays an important role in IL-2 
induction. Signalling via CD28 activates PI3K and promotes NF-κB nuclear localization 
where it induces IL-2 expression (Sanchez-Lockhart et al., 2004). Moreover, 
transcriptional factor B lymphocyte–induced maturation protein-1 (Blimp-1) expression 
is induced upon TCR stimulation and IL-2 production and has been shown to act as 
transcriptional repressor that attenuates IL-2 gene expression in IL-2 negative feedback 
loop (Martins et al. 2008; Gong and Malek, 2007). Thus, naïve Blimp-1-deficient CD4 T 
cells showed in steady-state higher amount of IL-2 mRNA expression in comparison to 
wild type CD4 T cells. Furthermore, IL-2 expression correlated inversely with Blimp-1 
expression upon OVA stimulation in both CD4 (Martins et al., 2008) and CD8 T cells 
(Gong and Malek, 2007). As we observed dampening of IL-2 production by Arl4d and the 
fact that Arl4d localizes to the nucleus (Lin et al., 2000), one could speculate that Arl4d 
functions as transcriptional repressor of the IL-2 gene, similar to Blimp-1, when it is 
localized to the nucleus.  
In summary, we have described that Arl4d is induced by PD-1 signaling and inhibits IL-2 
production by an as-yet unknown mechanism, which could be as diverse as modulating 
the inhibitory signaling pathway or inhibiting the mitochondrial function or even 
repressing the IL-2 gene. In order to assess whether one or a combination of these 
possible mechanisms play a role, more detailed studies are required.  
 
5.5 Composition of the peripheral lymphoid compartment in the absence of Arld4 
To be able to investigate the function of Arl4d in vivo, we obtained Arl4d-deficient mice 
that were generated according to the “knock-out first” strategy from International 
Mouse Phenotyping Consortium (IMPC). First phenotypical analyses of these Arl4d-
deficient mice revealed abnormalities in the skeletal phenotype (legacy data available 
from the IMPC website: http://www.mousephenotype.org), including decreased rib 
number, abnormal rib morphology in mutant males and decreased bone mineral content 
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in females. Furthermore, Arl4d-deficient mice are decreased in body weight and lean 
body mass. However, no overt changes in the immune system were reported by the 
IMPC. Our analysis of the peripheral lymphoid compartment confirmed that Arl4d-
deficiency does not interfere with T lymphocyte development; distribution and numbers 
of CD4 and CD8 T cells in both spleen and blood were normal and Arl4d-deficient T cells 
did not display skewed subpopulations as measured by the activation and memory 
markers CD44 and CD62L (Fig. 16). This is in contrast to PD-L1-deficient mice, which 
have more activated CD4 T cells and increased percentages of central memory CD8 T 
cells (Bazhin et al., 2014). Although PD-L1 expressed on LSEC can induce Arl4d 
expression in CD8 T cells, PD-L1 is broadly expressed and not only signals via PD-1 but 
also via CD80 (Butte et al., 2007; Park et al., 2010). Therefore, the phenotypes 
developing due to either deficiency do not need to overlap. 
In summary, our analyses showed that Arl4d had no major impact on the development 
of the peripheral T cell compartment in lymphoid tissues. 
 
5.6 Function of Arl4d via regulation of IL-2 production 
In the present study, we found that highly increased Arl4d expression can be found in 
LSEC-primed T cells, which are incapable of IL-2 secretion, and the opposite occurs in 
the absence of Arl4d, i.e. increased secretion of IL-2 after stimulation. Thus, Arl4d might 
be involved in immunological processes in which production or availability of IL-2 
regulate outcome. For instance, upon antigen encounter during infection IL-2 promotes 
development of naïve CD8 T cells into effector cells (Pipkin et al., 2010; Liao et al., 2013) 
and further drives the expansion and survival of CTLs (Mitchell et al., 2010). Therefore, 
we analyzed the role of Arl4d in primary viral infection model and could show that 
Arl4d decreased accumulation and expansion of antigen-specific CD8 T cells in the 
blood, spleen and liver upon adenovirus (AdGOL) infection (Fig. 18). These data are 
consistent with studies mentioned above and indicates that Arl4d may regulate IL-2 in 
this model by limiting the availability of IL-2. 
Nevertheless, we cannot exclude other processes that Arl4d could modulate, for instance 
apoptosis. After robust expansion, once the infection is cleared, 90-95% of effector CTLs 
die by apoptosis (Williams and Bevan, 2007; Stemberger et al., 2007). As we observed 
increased numbers of antigen-specific Arl4d-deficient CD8 T cells in AdGOL-infected 
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mice during the whole time investigated (until day 8), it is possible that those cells were 
less prone to apoptosis leading to their better survival on viral infection than wild type 
CD8 T cells. That would indicate higher intrinsic stability of Arl4d-deficient CD8 T cells 
and suggest that Arl4d could decrease CD8 T cell survival.  
Another explanation might be an increased proliferation potential of Arl4d-deficient 
CD8 T cells. CD8 T cells require only short antigen stimulation (about 2h) to become 
active and further proliferate autonomously without the necessity of additional antigen 
stimulation (van Stipdonk et al., 2001; Wong and Pamer, 2001). Co-transfer of wild type 
and Arl4d-deficient T cells into the same recipient ensures that both T cell populations 
occupy the same environment and have access to the same antigen levels and pro-
inflammatory cytokine surroundings. Also here Arl4d-deficient T cells expanded more 
than their wild type couterparts, suggesting that this increased expansion of Arl4d-
deficient cells may be cell-intrinsically regulated. It is thought that expansion of CD8 T 
cells upon infection is driven by autocrine IL-2. Upon LCMV infection increased numbers 
of LCMV-specific CD8 T cells were observed in a chimeric system when augmented 
autocrine IL-2 signals were delivered (Cheng and Greenberg, 2002). Consistent with 
these data, it has been shown that antigen-specific IL-2-/- CD8 T cells, unable to produce 
IL-2, expanded to lesser extent upon viral infection as wild type CD8 T cells (Feau et al., 
2011). As Arl4d-deficient CD8 T cells produce more IL-2, autocrine IL-2 may also lead to 
the observed enhanced expansion of CD8 T cells lacking Arl4d.  
In summary, here, we provide evidence that Arl4d function to inhibit expansion of 
antigen-specific CD8 T cells upon adenoviral infection. Based on our findings, we 
speculate that modulation of autocrine IL-2 production might influence the expansion.  
 
Following LCMV infection the majority of LCMV-specific effector CD8 T cells express 
KLRG1, a marker characterizing short-lived effector CD8 T cells (SLEC) (Joshi et al., 
2007). These SLEC can be distinguished from memory precursors (MPEC) by their 
surface expression of KLRG1 and CD127 (SLEC are KLRG1highCD127low). In our study, we 
examined development of KLRG1highCD127low CD8 T cells and found that both 
transferred wild type and Arl4d-deficient CD8 T cells developed into SLECs upon AdGOL 
infection. Interestingly, higher percentages and numbers of CD8 T cells expressed 
KLRG1 when Arl4d was lacking, indicating that Arl4d could limit effector CD8 T cell 
development (Fig. 22). An important role of IL-2 signals to promote differentiation of the 
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SLEC population has been suggested. CD25-deficient CD8 T cells (cells lacking IL-2 
receptor) showed decreased development of KLRG1high CD127low cells at the peak of 
viral and bacterial infection (Obar et al., 2010; Pipkin et al., 2010). Thus, Arl4d may limit 
SLEC development by modulating IL-2 production during infection.  
Expression of the transcription factor T-bet correlates with SLEC development and 
clonal expansion, whereas MPEC development depends on Eomes expression (Joshi et 
al., 2007; Takemoto et al., 2006). LSEC-primed CD8 T cells, in which Arl4d is 
overexpressed, express Eomes but not T-bet (Böttcher et al., 2013). Although we did not 
analyze T-bet expression in Arl4d-deficient SLEC, we did observe increased SLEC 
development when Arl4d was absent, suggesting that Arl4d could down modulate T-bet 
expression and thereby dampen effector T cell differentiation and/or expansion. 
 
Take together, the present work shows that the unique differentiation state of LSEC-
primed CD8 T cells requires integration of co-inhibitory PD-L1/PD-1 signaling for 36 
hours after which this particular differentiation program cannot be reversed by co-
stimulatory signaling. In such LSEC-primed T cells the small GTPase Arl4d is PD-L1-
dependently induced, which may have a more general role in T cell immunity via 
regulating IL-2 availability. Therefore, Arl4d might play an important, as-yet 
undiscovered, role in the inhibitory PD-L1/PD-1 pathway and possibly serve as a 
modulator of CD8 T cell immune responses. 
 
5.7 Future perspectives 
In our work, we focused on the role of Arl4d in the CD8 T cells immune response on 
primary viral infection. After acute infection, most of the antigen-experienced CD8 T 
cells (90-95%) undergo apoptosis, however, a small percentage survives and forms a 
long-lived memory population (Obar et al., 2008; Stemberger et al., 2007; Kaech and 
Wherry, 2007). IL-2 signals in the primary infection are required not only for the 
development but also for the function of memory CD8 T cells on secondary infection 
(Mitchell et al., 2010; Pipkin et al., 2010). In addition, not IL-2 produced by DCs or CD4 T 
cells is crucial for the secondary expansion but the autocrine IL-2 produced by CD8 T 
cells (Feau et al., 2011). Based on our and those findings we assume that Arl4d might 
also affect the memory formation during primary infection and memory CD8 T cell 
Discussion 
 
85 
 
expansion during the secondary infection. Therefore, future studies should focus on the 
aspect of memory formation.  
 
Here, we demonstrate the role of Arl4d in dampening of IL-2 production in CD8 T cells, 
However, we have not investigated whether Arl4d plays role in the development or 
functionality of other cell populations. Although Arl4d does not influence CD4/CD8 
distribution both in the thymus (data not shown), spleen or blood, we have not 
investigated particular subpopulations, including Tregs. Natural Treg (nTreg) 
precursors (CD4SP CD25hi) require IL-2 signaling for the upregulation of Foxp3 
expression and their further expansion (Malek et al., 2002; Lio and Hsieh, 2008). 
Moreover, IL-2 is crucial for the maintenance of nTregs in the periphery and their 
functionality (Setoguchi et al., 2005; Fontenot et al., 2005). Apart from nTregs, IL-2 is 
essential for the development of Tregs from conventional CD4 T cells in the periphery 
(inducible Tregs, iTregs) (Almeida et al., 2002). Here besides TCR signaling, Foxp3 
expression is induced by TGF-β and this process is strongly IL-2-dependent (Davidson et 
al., 2007). Interestingly, iTregs express high levels of PD-1 and recent studies showed 
the role of PD-L1/PD-1 pathway in the development of iTregs (Francisco et al., 2009). As 
Arl4d expression is induced on PD-L1/PD-1 interaction, it would be interesting to 
investigate whether Arl4d influences the development of Tregs and whether it plays a 
role in central and peripheral tolerance.  
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0C Celsius grade 
Ab antibody 
AdGOL Adenovirus expressing GFP, ovalbumin and luciferase 
AIRE autoimmune regulator 
APC antigen-presenting cell 
ARF ADP-ribosylation factor 
ARL ADP-ribosylation-like factor 
B7H1 B7 homolog 1 
Blimp-1 B lymphocyte–induced maturation protein-1 
BSA bovine serum albumin 
CD cluster of differentiation 
CCR CC-chemokine receptor 
CCL CC-chemokine ligand 
CTL cytotoxic T lymphocyte 
CTLA-4 cytotoxic T lymphocyte antigen 4 
DC dendritic cells 
DMEM Dulbeccos Modified Eagle Medium 
DP double-positive thymocyte 
EDTA Ethylendiamintetraacetat 
ELISA Enzyme-Linked Immunosorbent Assay 
ER endoplasmic reticulum 
ESCRT endosomal sorting complex required for transport  
et al. and others (lat. et alii) 
FACS fluorescence activated cell sorter 
GAP GTPase-activating protein 
GBSS Gey’s balanced salt solution 
GEF guanine exchange factor 
GDP guanosine diphosphate 
GTP guanosine triphosphate 
GzmB granzyme B 
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h hour 
HRP horseradish peroxidase 
HSC hepatic stellate cell 
ICAM-1 intracellular adhesion molecule 1 
IPMC International Phenotyping Mouse Consortium 
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ITSM immunoreceptor tyrosine- based switch motif 
IFN interferon 
Ig immunoglobulin 
IL interleukin 
i.p. intraperitoneal 
i.v. intravenous 
IS immunological synapse 
ITAM immunoreceptor tyrosine-based activation motif 
l liter 
LAT linker for activation of T cells 
Lck lymphocyte-specific protein tyrosine kinase 
LCMV lymphocytic choriomeningitis virus 
LFA-1 lymphocyte function-associated antigen 1 
LPS lipopolysaccharide 
LSEC liver sinusoidal endothelial cells 
μ micro 
m mili  
M Molar 
MACS magnetic activated cell sorter 
min minutes 
mRNA messenger ribonucleic acid  
mTEC medullary thymic epithelial cell 
MHC  major histocompatibility complex 
MHC I MHC class I molecules 
MHC II MHC class II molecules 
MTOC microtubule network position microtubule organization 
center 
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n nano 
NF-κB nuclear factor 'kappa-light-chain-enhancer' of activated B 
cells 
NK natural killer cells 
NKT natural killer T cell 
NLS nuclear localization signal 
OD optical density 
OVA ovalbumin 
OXPHOS mitochondrial oxidative phosphorylation 
PAMP pathogen-associated molecular pattern 
PBS phosphate buffered saline 
PD-1 programmed cell death 1 
PD-L programmed cell death ligand 
PFA paraformaldehyde 
PFU plaque forming units 
PI3K phosphatidylinositol 3-kinase 
PKCθ protein kinase C-theta 
PLCγ phospolipase C-gamma  
PMA Phorbol-12-myristate-13-acetate 
POX peroxidase 
PRR pattern recognition receptor 
rpm revolutions per minute 
ROI region of interest 
ROS reactive oxygen species 
RT room temperature 
s seconds 
SD standard deviation 
SEM standard error of the mean 
SHP-2  Src homology 2 (SH2)-domain-containing protein tyrosine 
phosphatase 2 
SLP-76 Src homology 2 (SH2) domain-containing leukocyte 
phosphoprotein of 76 kDa 
SMAC supramolecular activation cluster 
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TBS tris buffered saline 
TCR T cell receptor 
TGFβ transforming growth factor-beta 
TGN trans-Golgi network 
Th1 type 1 T helper cells 
Th2 type 2 T helper cells 
TIRF total internal reflection fluorescence microscopy 
TLR Toll-like receptor 
TNF tumor-necrosis factor 
TRA tissue-restricted antigen 
Treg T regulatory cell 
nTreg natural T regulatory cell 
iTreg inducible T regulatory cell 
VPA valproic acid 
ZAP-70 non-receptor tyrosine kinase ζ-associated protein of 70 kDa 
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